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Sumário 
 
Esta tese centra-se particularmente na área da Economia da Saúde. Todavia, a 
mesma pode ser decomposta em duas partes autónomas. 
A primeira parte, que corresponde ao capítulo 2, é um estudo essencialmente teórico 
sobre o desenvolvimento do que hoje conhecemos como Economia da Saúde, dando 
especial atenção não só à sua origem como também ao papel desempenhado pelas novas 
Tecnologias da Informação e Comunicação (TICs) na Economia da Saúde e nos cuidados 
de saúde. 
A segunda parte, que é constituída pelos capítulos 3 e 4, tem uma natureza 
essencialmente empírica. 
No capítulo 3, determinam-se os principais fatores, que ao longo das últimas 
décadas contribuíram para o aumento das despesas em saúde, dando especial enfâse ao 
impacto das TICs no sector. Este estudo distingue-se da restante literatura através do uso de 
uma “base de dados completa” suportada pela múltipla imputação e através da construção 
de um índice tecnológico capaz de refletir o papel das TICs no sector da saúde. Os 
resultados obtidos permitiram concluir que o recurso a dados em painel e à múltipla 
imputação pode ser uma abordagem viável para a análise da tendência das despesas em 
saúde. 
O último estudo procura não só determinar se a preocupação atual à volta do 
montante das despesas em saúde é realmente legítima, mas também procura avaliar o 
retorno de tal despesa em termos quantitativos (esperança média de vidas) e qualitativos 
(morbidade e incapacidade). Para tal, construiu-se um novo indicador do estado da saúde da 
população capaz de combinar, no mesmo indicador, mortalidade e morbidade. Recorrendo 
a uma vasta base de dados em painel, constituída por 30 países da OCDE, estimou-se a 
influência de determinadas variáveis socioeconómicas, ambientais, de estilo de vida e 
tecnológicas no indicador em questão. 
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Summary 
 
The central theme of this thesis is within the field of Health Economics. However, 
we can decompose it into two independent parts. 
The first part (Essay 1) is essentially a theoretical essay about the development of 
what we know today as Health Economics, highlighting not only its origin and its leading 
authors - and what they defended-, but also the role of the development of Information and 
Communication Technologies (ICTs) for Health Economics and Healthcare. 
The second part (Essay 2 and Essay 3) has an empirical nature. 
In the second essay, we determine the main factors that, over the last few decades, 
have contributed to the increase in healthcare spending, focusing especially on the impact 
of technological innovation on the healthcare sector. This essay differentiates itself from 
the literature by using a “complete panel dataset” supported by multiple imputation and 
through the construction of a technological composite index able to account for the role of 
new technologies in the healthcare sector. The results obtained suggest that the use of panel 
data and multiple imputation techniques may be a viable approach to the analysis of trends 
in healthcare expenditure. 
The last essay tries not only to determine if the concern that nowadays surrounds 
healthcare expenditure is really legitimate, but also to evaluate the return of such 
expenditure in quantitative (life expectancy) and qualitative (morbidity and disability) 
terms. For that, we construct a new health status indicator able to combine mortality and 
morbidity into a single composite measure. Using a large panel data of thirty OECD 
countries, we estimate how various socio-economic, environmental, lifestyle and 
technological factors affect the health status indicator. 
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Chapter 1 
1. Introduction 
 
The aftermath of World War II initiated a period of incredible economic growth, 
due in large part to a boom in technological advances and changes across virtually all 
sectors of the global economy. More specifically, the global healthcare system also 
experienced a profound transformation during this same timeframe, namely across the 
developed world. During this time, Developed countries managed to achieve high growth 
rates in total healthcare expenditures, coupled with an exponential increase in the 
introduction and implementation of health technologies. As such, the emergence of several 
drugs, supplementary means of diagnostic, and surgical equipment, invariably contributed 
not only to the improvement of diagnosis, treatment and the quality of information, but also 
to the overall growth of healthcare expenditures. 
The growth of healthcare spending associated with the economic slowdown in 
developed countries has long since attracted the attention of people, specifically health 
economists (Mushkin, Lees, Arrow, among several others), organizations and 
policymakers, whose principal concerns were to understand and analyze such phenomena. 
According to the Organisation for Economic Co-operation and Development (OECD), the 
growth in health spending exceeded the growth of Gross Domestic Product (GDP) in 
almost all OECD countries over the past fifteen years and could grow by another 50 to 90 
percent by 2050 (OECD, 2009).  This growing interest on health sector has since led to the 
inception of the discipline of Health Economics as an autonomous branch within the field 
of economics. 
Beginning in the 1960s, initial studies started to appear with the main aim to 
understand and restrict healthcare spending growth. Overall, these inaugural studies 
analyzed the influence exerted by certain measurable and non-directly measurable variables 
on healthcare spending. Indeed the prevailing literature has sought to study the 
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determinants of growth in healthcare costs through the use of different methodologies – 
these studies share some consistent conclusions identifying the paramount drivers 
responsible for this growth. For example, authors agree that the effect of income on health 
expenditure is positive and significant; i.e. aging population plays only a minor role in 
increasing cost, while the existence of ‘gatekeepers’ helps to reduce costs despite being 
routinely insignificant. Furthermore, public sector provisions of healthcare services was 
widely agreed to increase health expenditures, identifying technological change as the most 
important impetus for spending increases over time (Gerdtham and Jönsson, 2000). 
However, one of the major problems surrounding the enigmatic growth of 
healthcare spending is the inherent difficulty in measurements of quantitative and 
qualitative returns of invested values. As such, there is a problem in understanding 
precisely how effective this spending is, asking the question: what is a plausible means of 
evaluating the economic return of these investments and the possible contributions of this 
increase relative to spending on health. 
The nature and magnitude of such concerns raise some important questions about 
the amount of healthcare spending – from what point can we say that such expenditures are 
considered ‘high’? Is there truly an equilibrium for health expenditure? Is this concern 
about healthcare sector legitimate? What in fact are the negative ramifications, if any of 
high healthcare costs? 
This thesis is comprised of four chapters, along with an introductory chapter – the 
remaining chapters cover the following topics: 
Chapter 2 is a background about the evolution of Health Economics as an 
autonomous branch within the larger field of Economics, highlighting not only its origin 
and the leading authors who pioneered the discipline, but also the impact and the role of the 
Information and Communication Technologies development on the Health Economics and 
healthcare sector. 
The purpose of chapter 3 is to determine the main factors that, over the last few 
decades, have contributed to an increase in healthcare spending, with particular attention 
Introduction 
3 
 
paid on the impact of technological innovation across the healthcare sector. This study 
differentiates itself from the prevailing literature by using a “complete panel database”, 
supported by multiple imputations through the construction of a technological index that 
are effectively able to account for the role of new technologies across the healthcare sector.  
The analysis and subsequent results present both robust and interesting results, 
suggesting that the use of panel data and multiple imputation techniques may be a viable 
approach to the analysis of trends in health expenditure. Furthermore, many of our 
conclusions corroborated findings in the literature such as Barros (1998) and Okunade et al. 
(2004) – others results regarding the influence of technology were not relevant. The study 
also found that technological innovation has a differential positive impact on costs, 
dependent on a country’s stage of development of technology, i.e. increases in the health 
expenditure per capita were driven by technological innovation, exhibiting diminishing 
returns, 
Finally, in chapter 4, we attempt to determine if concern surrounding healthcare 
spending is legitimate whereby evaluating the return of such spending in quantitative (life 
expectancy) and qualitative (morbidity and disability) terms. For this test, we construct a 
new health status indicator that combines mortality and morbidity into a single composite 
measure.  
According to the consequent analysis performed, we concluded that the concern 
around the amount of health care spending per capita should not be focused on the total 
expenditure per se, but instead directed to the amount financed by the government. 
 
 
 
JEL classification: C87, I10, N01, O33. 
Keywords: Health Economics, Healthcare Economics, Information and Communication 
Technologies (ICTs), Multiple Imputation, Technological Innovation, Healthcare Costs
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Chapter 2 
 
 
 
2. Why and how did Health Economics Appear? Who 
were the Main Authors? What is the Role of ICTs in 
its Development?

 
 
  
                                                          

 This is a joint paper with Ana Pinto Borges and it was published in “Handbook of Research on ICTs and 
Management Systems for Improving Efficiency in Healthcare and Social Care”, edited by Maria Manuela 
Cruz-Cunha, Patrícia Gonçalves and Isabel Miranda, IGI Global. 
We thank Fundação para a Ciência e Tecnologia, FEDER and FSE for research grant PTDC/EGE-
ECO/114881/2009 and SFRH/BD/63309/2009. We are grateful to Cláudia Cardoso, João Correia-da-Silva, 
Pedro Rodrigues and Pierre Polzin for useful comments and suggestions. 
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2.1 Introduction 
 
The end of World War II signaled a new era in technological innovation and 
economic growth that permeated virtually all sectors of the world economy. One such 
sector that yielded an extraordinary transformation in this regard was the Healthcare 
system. 
Developed countries thus experienced not only abrupt advances in medical 
knowledge, but also the genesis of Information and Communication Technologies (ICTs) in 
the health sector, which instigated numerous changes in management and political beliefs. 
Such changes were also reflected in their respective national accounts which attracted the 
attention of several institutions and economists (Mushkin, Lees, Arrow, among several 
others), with the aim of disseminating the mechanisms behind this phenomenon, thus 
paving the way for the emergence of health economics as sovereign field within the 
overarching mantle of economics. According to the Organisation for Economic Co-
operation and Development (OECD), growth in health spending exceeded growth of Gross 
Domestic Product (GDP) in almost all OECD countries over the past fifteen years and 
could grow by another 50 to 90% by 2050 (OECD, 2009). 
In this chapter, we focus on the origins and subsequent development of Health 
Economics as a social science, reflecting on the role played by leading authors that 
emerged in the field, while also tracing the development of ICTs across health economics 
and healthcare. In this sense, it is worth noting that in the last few decades, there have been 
substantial increases in the utilization of health technologies, as well as the emergence of 
myriad drugs, and supplementary means of diagnosis and surgical equipment, among 
others. 
Indeed, the aggregative effect of innovation on the health sector allowed for 
different entities such as governments, healthcare providers, and patients to collectively 
reap the benefits from a cascade of higher-quality health services. However, despite all the 
latent advantages associated with the introduction and implementation of these innovations, 
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the use of ICTs across the health sector itself still remains largely limited in several areas, 
due in large part to the existence of some barriers inherent to the sector. 
The next chapter is organized as follows: Section 2.2 outlines the origin of health 
economics along with the acute differences between health economics and healthcare 
economics. In section 2.3, we explore the development of ICTs and its role in the health 
economics sector, coupled with the limited use of ICTs – the final section offers concluding 
remarks. 
 
 
2.2 The Origin of Health Economics and the Leading 
Authors  
 
Issues related with the quality, effectiveness, and overall efficiency of the health 
sector, notably with respect to the level of costs, has been a familiar theme in the political 
agenda of many countries. This growing trend, which when verified by mounting health 
expenditures, attracted the attention of different academics and researchers, with the 
singular aim of pinpointing the underlying causes of this rampant growth and the hopes of 
controlling for such phenomenon (Mehrotra et al., 2003). 
Seemingly runaway healthcare costs across several regions also drew the attention 
of some organizations such as the Institute of Economic Affairs
1
 in London and the Ford 
Foundation
2
, raising notable concern amongst policymakers. It is important to note that the 
existence of high healthcare costs did not in and of itself elicit the concern of these 
individuals, but rather a runaway effect in the nature of rising prices themselves. 
                                                          
1
 The Institute of Economic Affairs is a United Kingdom’s original free-market police institute, founded in 
1955. Its mission is to improve understanding of the fundamental institutions of a free society by analyzing 
and expounding the role of markets in solving economic and social problems. 
2
 The Ford Foundation is a private foundation incorporated in Michigan and based in New York City by Edsel 
Ford and Henry Ford to “receive and administer funds for scientific, educational and charitable purposes, all 
for the public welfare”. 
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Researchers can generally mark the period immediately following World War II as 
the beginning of ascending health spending in most of the world’s industrialized countries. 
Some works done in the area attribute a large portion of the growth observed in health 
spending to substantiated advances in medical knowledge, as new medical procedures and 
drugs (Cutler, 1995; Matteo, 2005; Okunade and Murthy, 2002). Indeed, the introduction of 
new and sophisticated medical technology is hardly an isolated occurrence, namely as 
initial expenses and installation costs of new equipment in the medical high has historically 
been rather high. 
According to some forecast studies, the emergence and consequent adoption of new 
medical technologies and services were the paramount factors responsible for such growth, 
constituting roughly half of the increase witnessed in healthcare expenditures during the 
past few decades. For Cutler (1995) the adoption of new technology in the healthcare sector 
has contributed in a 45% increase in the total growth of real healthcare spending per capita 
in the USA between 1940 and 1990. In turn, Newhouse (1992) estimates an increase over 
65%. 
It was in this social, political, and economic context that, in 1948 the National 
Health Service (NHS) – a program for health – was created in England, which served as a 
watershed year for the field of health economics in that several other countries followed 
shortly after. The NHS’ core principles were: universal coverage and equitable access 
according to need. 
However, over time the increased availability of drugs, such as antibiotics 
(developed by Fleming in 1928 and Florey and Chain in 1939), better anaesthetics, the use 
of insulin in the treatment of diabetes (Banting and Best, 1922), effectively helped drive up 
the costs incurred by the NHS. These increases were further compounded by the more 
widespread offerings of cortisone, the polio vaccine, treatments of mental illnesses such as 
depression, antihistamines, as well as all other advances (including improved radiology 
systems, dialysis for chronic renal failure, and chemotherapy, among many others, which 
collectively threatened to jeopardize the service’s overall mission. 
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At this same time, the United States faced similar issues of its own, leading to the 
establishment in 1965, of a social insurance program designed to provide for the needs of 
all elderly adults through the availability of comprehensive healthcare coverage at an 
affordable cost – tabbed as the Medicare system. This program and its sister program, 
Medicaid, were enacted by President Lyndon Johnson as part of his “Great Society”, a 
period of widespread social change. In 1972, Medicare eligibility was extended to two 
other groups as well, helping individuals who also faced similar barriers in obtaining 
reliable health coverage – people with disabilities and people with terminal renal disease. 
As early as the 1950s and 1960s, healthcare established itself as a central economic 
issue worldwide. It was also during this same time period that several publications became 
commonplace, attempting to explain and analyse the system itself. With a renewed focus on 
its citizenry in the aftermath of the Second World War, politicians and economists’ 
speeches began to reflect a marked improvement in public health thorough the targeted 
reduction of disease, debilitation and premature mortality, with the aim of promoting 
economic growth through the preservation and strengthening of their respective workforce. 
This ideology was also associated with the rationalization, conceptualization, and 
professionalization of health, which helped launch the emergence and proliferation of 
global health organizations. 
According to Mushkin (1958), this growing interest in the health sector coincided 
with the need to respond to emerging problems handicapped by issues of financing and 
with two developments that were both inherent to scientific advances in medicine. First, 
new therapeutic products helped combat diseases that served as an ever-present spectre 
contributing to the leading causes of death in countries such as the US and other industrial 
nations. Furthermore, countries actively sought to address the possibility of increasing life 
expectancy. 
Mushkin (1958) was the first person to write about health economics having also 
provided the first concrete definition of the field, this is, Health Economics “is a field of 
inquiry whose subject matter is the optimum use of resources for the care of sick and 
promotion of health. Its task is to appraise the efficiency of the organization of health 
services and to suggest ways of improving this organization” (Mushkin, 1958, pp. 790). In 
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1958, she published her paper, Toward a Definition of Health Economics, in Public Health 
Reports, and outlined the difference between medical market and the classical economics 
market. 
The main ideas to distinguish the medical market and classical economics market 
were: “First, the profit motive is not adequate as an explanation of the activity in medical 
“market”… Second, in medicine, price is not the sole means by which demand and supply 
of medical and health services may be equated…Third, medical services are personal 
services…Fourth, consumers do not choose between health services and other goods and 
services by means of a simple rational weighing of choice…the consumer prefers to avoid, 
or remove the circumstances that compel, using resources for health purposes.”(Mushkin, 
1958, pp. 786-787). 
Other publications of note included a British study through the Institute of 
Economic Affairs, in the form of a Hobart Paper by Dennis Lees (1961) called Health 
through Choice that voiced the first concerns over health in the economy (Williams, 1998). 
Later, the most important of Lees’ ideas presented in that paper were adopted in the US by 
Arrow’s famous 1963 American Economic Review article, Uncertainty and Welfare 
Economics of Medical Care, and then later by Culyer in Britain (Williams, 1998). 
Arrow (1963), considered by many to be the founder of health economics, wrote 
about several issues that characterize this research field itself, such as the role of 
uncertainty on the effectiveness of healthcare, the agency problem both between doctor and 
patient and between doctor and health insurance and physician’s behavior, risk aversion, 
moral hazard, asymmetrical information, and philanthropic externalities, among many other 
issues. 
Arrow’s principal objective was to show that the healthcare market differed from 
the competitive model that maximized welfare. He called particular attention to the fact that 
the “... subject is the medical-care industry, not health. The causal factors in health are 
many, and the provision of medical is only one. Particularly at low levels of income, other 
commodities such as nutrition, shelter, clothing, and sanitation may be much more 
CHAPTER 2 
11 
 
significant. It is the complex of services that center about physician, private and group 
practice, hospitals, and public health...”(Arrow, 1963, pp. 941). 
Despite the first reference made by Lees (1961) and the fact that the ideas 
developed by Mushkin (1958) were quite close to the main ideas present in Arrows’ paper 
entitled, “Uncertainty and the Welfare Economics of Medical Care”, the foundation of 
Health Economics as a discipline is still attributed, by many, to Arrow (1963). The 
association of the origins of health economics to Arrow and not to Mushkin or Lees are 
likely due to several factors, which included the fact that Mushkin’s (1958) article was 
published in the Public Health Reports, a relatively obscure periodical at this time, coupled 
with the fact that Lees (1961) makes no mention of uncertainty as an economic 
characteristic of health, something discussed by Arrow (1963) in great detail in his work. 
In this context, health economics appears as a branch of economics, defining itself 
as the study of how limited healthcare resources ought to be used to meet our needs, 
leading to the adaptation, by health economists, of a very ‘medical’ model of health, where 
healthcare appears as an intermediate good without intrinsic value in itself but necessary in 
the production of health itself (Edwards, 2001). In the analysis of such definitions, we can 
deduce an essential distinction between two possible fields contained in Health Economics: 
healthcare and health as a standalone entity. 
The first notion of Health Economics divided in two separate fields of research 
appears in Mushkin (1958) with the statement: “The subject matter of health economics 
includes factors that determine price patterns for health services, ways in which the 
materials, goods...are brought together at the right time and place and in the right 
proportions to provide health services... The mechanisms by which goods and services are 
coordinated are “trade” in the market by the consumer’s purchase of health goods... 
Health economics also includes in its subject matter the effects of health services on the 
size, character, and efficiency of the work force and population” (pp. 791-792). 
This distinction also appeared in Arrow (1963) with the evidence: “It should be 
noted that the subject is the medical-care industry, not health” (pp. 941). The same vision 
was shared by Grossman (1972a and 1972b) - according to him, we can see health as a 
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general concern and healthcare as just one of the inputs for health - (Fuchs, 2000; Maynard 
and Kanavos, 2000; Phelps, 1995; Williams, 1993). All these visions connected almost 
exclusively the discipline to healthcare, that is, they argued that the focus of health 
economics would be almost exclusively on the production, distribution and organization of 
healthcare. However, the concepts ‘health economics’ and ‘healthcare economics’ only 
began to be used distinctly from Edwards (2001). 
Nowadays, this distinction is widely visible across research areas, as it is usual to 
see papers classified either health or as healthcare, disaggregated between research 
dedicated to the realm of health and the others solely focusing on healthcare (Cardoso, 
2008). Thus, we are not stating that a complete schism exists between the two disciplines 
rather that the two do share some common components where knowledge can be shared. 
In relation to public concerns, healthcare has been more predominant than health 
due to methodological and conceptual issues. The availability of data about healthcare and 
the existence of specific tools to deal with the data create an opportunity for research – 
studying demand for healthcare involves fewer risks than studying demand for health. 
Furthermore, the need for responses about health market failures and the role of public 
intervention to effectively provide healthcare for citizens constitutes yet another reason for 
the dominance of healthcare economics. 
To this end, we can say that a market can exist for healthcare, but not for health, 
where healthcare appears as an input that is necessary to produce health, with others goods 
and social factors (Edwards, 2001). As we will see outline below, over time, the 
determinants of health have been dynamic and fluid, fluctuating in perceived significance 
over time. 
One of the paramount factors responsible for achieving high levels of public health 
(social model) was a shift in overall habits by researchers, thanks in large part to the 
advances verified at the medical (Biomedical model) and technological (eHealth) level. 
Moreover, ICTs have also yielded an important impact over time in the healthcare sector, 
not only in maintaining cost efficient and high quality health and social care, but also in the 
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empowering people of every age to better manage their health and quality of life. Later 
sections will be given a special emphasis and focus on the impact of ICTs in the health 
sector. 
 
 
2.3 ICTs: Their Development and Their Role in the Health 
Care Sector 
 
The improvement in living conditions of the populations associated with the 
emergence of chronic illnesses resulting from the increase in longevity has changed 
people's overall attitude and perception towards healthcare. More and more people, instead 
of simply receiving treatments for their illness, began to give more importance to high 
quality preventive healthcare over time. 
The existence of demanding and better-informed patients in terms of quality, 
associated with the need to control costs in the health sector, also led to the creation of a 
need to invest in processes/infrastructures that were able to increase the quality of care in a 
more efficient and effective way (improve productivity, efficiency and patient focus). 
Historical data concerning the evolution of populations reveals that, after the second 
half of the twentieth century, the world witnessed a significant improvement in overall 
health status across populations, which was reflected in a significant reduction in mortality 
and progressive increases in longevity (World Health Organization, 2010). 
The reasons behind these improvements are not consensual among academics and 
researchers, some of which argue that the improvement verified in populations’ health 
status was achieved due to technical developments in medicine – the Biomedical model. 
Others, argue that such phenomenon were due to social advances verified in the living 
conditions of populations – social model of health (McKeown and Lowe, 1974). 
The Biomedical model was a product of the seventeenth century that interpreted 
medicine as an activity closely linked to the exercise of professional power, due to the fact 
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that control over health and disease was increasingly practiced by health professionals in 
detriment of the people themselves. In this model, biological factors were only responsible 
for the health status of the patient, excluding any kind of psychological, environmental, 
political, and social factors. 
Alternatively, the Social model emphasizes the role developed by factors such as 
better nutrition, personal hygiene, social and environmental background, sanitation, level of 
education and information, etc., relegated to the health status of the patient. The principles 
underlying this model are also more tangibly analyzed and seen, if only by the fact that the 
improvement of the population’s health status has begun, roughly a century before the 
medicine has had effective means of fighting diseases. 
The ideology underlying the Social model of health is also present in the definition 
of health by the World Health Organization (1948): “Health is a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity”. To be 
considered a healthy individual, he or she needs to be well not only physically and 
psychologically but also being in balance with the environment that surrounds him, with no 
signs or symptoms of diseases. 
According to the Social model, to be possible to obtain a high level of health, a 
connection between the health sector and all other sectors related to development is 
necessary. This process involves not only governments, through the implementation of 
healthy public policies (including reforms in the environmental area, slum clearance, 
improved sanitation, and clean air), but also all the overarching community (with changes 
in the individual behavior in health – family planning, accident prevention, weight control, 
alcohol consumption and smoking). 
Simultaneously to advances across the health sector, living conditions of 
populations were also experiencing substantiated improvement. However, marginal gains 
derived from this improvement in the population health eventually reached a threshold, 
paving the way for technological innovation in healthcare as the main catalyst for 
development in the sector. 
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In addition to increases in life expectancy, the rise in the complexity of medical 
procedures and the emergence of new chronic diseases over time created a dilemma in the 
expenditures of countries' health systems, revealing the need to reduce costs in this sector. 
In essence, ensuring the sustainability of health systems and the growing demand for 
healthcare with more quality at affordable prices are were engrained as necessities, 
eventually pressing governments to effectively and efficiently manage the health sector, not 
only in qualitative and safety terms but also at the level of resources utilized. 
The roots of modern health however can trace its origins back much further, having 
risen as a product of the Industrial Revolution, whereby developed countries started to 
invest in health technologies with the main goal of addressing the problems demonstrated 
by the sector (accessibility, quality and costs). This health industrialization allowed for the 
facilitation and emergence of new knowledge, procedures, and specific equipment to the 
area. 
The first technologies had their main focus on the doctor and the disease, the patient 
being seen as something external to this relationship. Only later in time was a patient-
oriented approach adopted (healthcare networks and electronic medical records, for 
example), which nowadays has evolved to a more focused approach on health and the 
citizen itself, with the fundamental aim of giving the patient a more active role in managing 
their health at home, or in their respective environment. However, due to the importance 
and weight that knowledge, information and communication have gradually acquired in the 
medical domain, some of the resources devoted to innovation have been focused in the 
ICTs, with the main objective of ensuring an effective and quick dissemination and switch 
of ideas. 
ICTs is a generic term that includes any communication device or application, 
including computers and network hardware and software, cell phones, radio, television, 
satellite systems as well as the various services and applications associated with it, such as 
videoconferences. Although these technologies are present in different sectors, in this paper 
we will focus on ICTs in the context of health care, which is eHealth. 
Why and how did Health Economics Appear? Who were the Main 
Authors? What is the Role of ITCs in its Development? 
 
16 
 
ICTs offer the integration of some already existing technologies, such as telephone 
or Internet services, into medical practice to help foster a significant difference in the 
access, efficiency, effectiveness and quality of clinical processes and in the patients’ health 
condition. Nowadays, it is commonplace to see different personnel in the health sector 
using the internet for marketing purposes, not only to obtain medical information or 
consultation, but also to prescribe medicines, which reflects the influence exerted by the 
ICTs in the medical care provision.  
In this sense, the current implementation of the ICTs across the health sector 
contributes to the mitigation of costs, coupled with increases in the quality of services 
provided. Moreover, the optimization of decision-making by health professionals and the 
reduction of medical errors offer a more economical approach to resource management 
(with the aim to control costs, as this sector is very important in terms of public 
expenditure). In any scenario, it has been observed that better training and the transmitting 
of knowledge amongst health workers through mechanisms such as e-learning can help 
fortify healthcare systems by upgrading the management of information and timely access 
to that information, including improved diagnoses and a modernized approach towards 
patient notes using wireless Personal Digital Assistants (PDA), among many other useful 
utilities. 
Through these tools and advancements, it may be possible to improve the efficiency 
and safety in prescribing treatments and medicines using technology-based electronic 
prescriptions (“e-prescribing”), while also enhance clinical quality and the financial 
viability of the practice. In addition, the advent of technology has also led to higher quality 
medical services through improved channels of information and the reduction of 
duplicative documentation, which ultimately helps streamline the information exchange 
between providers internally and through different organizations, at both a regional and 
nationwide level, through a comprehensive network. Indeed, all organizations can benefit 
from greater efficiency measures and through the reduction of costs associated with 
providing services (European Commission, 2004). 
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This trend had not gone unnoticed and the European Commission in 2004 
recognized the role of the new ICTs applied to health, namely eHealth, as an effective and 
efficient mean to overtake and respond to challenges in the health industry. eHealth 
encompasses all the ICTs tools and services for health used behind the scenes by healthcare 
professionals, or directly by patients, which help improve the health of citizenry on a global 
scale. Through the use of ICTs, responsible authorities also want to enhance healthcare 
quality and reduce healthcare costs, thereby improving the efficiency with which healthcare 
is delivered and reducing the delivery of services with little or no value (European 
Commission, 2004). 
eHealth technologies appeared as the result of academic research concerned with 
imaging applications and laboratory automation. The successful use of the X-Ray (first 
used in 1895) for diagnostic purposes early in the twentieth century contributed/encouraged 
the introduction of new technology such as ultrasound (1942), and Magnetic Resonance 
Imaging (1973) to support diagnoses and the treatment of diseases. These are still 
considered new techniques, given that computed tomography scans, organ transplants, 
arthroscopic surgery, and selective serotonin reuptake inhibitors were uncommon or 
virtually unknown fifty years ago. 
eHealth at its core is about modernizing health system methods and technologies to 
increase the quality, safety, timeliness and efficiency of health service, including all 
medical healthcare services and technologies that rely on modern information and 
communication technologies, which implies something more than the simply Internet-based 
applications. The efficiency in the provision of healthcare implies a creation of an effective 
integrated system of information’s transmission in this sector. It is critical to ensure timely 
and accurate collection and exchange of health data, since the health sector is information 
intensive. Newer generations of ICTs are also able to promote transmission of information 
between the different channels in the health sector, which can reduce the operative and 
administrative cost through the monetary and timesavings on the patient information’s 
process. This is reflective in the reduction in the number of documents on paper (electronic 
billing, for example). However, for this approach to be possible, it is necessary to create a 
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national and/or international easily accessible communication network, containing the most 
relevant information about patients. 
Additionally, the use of the ICTs as a strategic tool in the promotion of safer, and 
more adequate healthcare enables industry professionals to spend more time with their 
patients and to adapt healthcare to individual needs using available resources more 
efficiently and effectively. eHealth also includes not only tools for health professionals but 
also for patients (personalized health systems), enabling the promotion of patient’s 
autonomy (raise the involvement of patients and responsibility for their own health). This 
autonomy, associated with the development of a communication system that is capable of 
providing timely and specific information to the patients, can be a possible way to reduce 
costs in the sector. Thus, we may defer to ICTs in order to enhance patients' autonomy in 
managing their own health through the use of opportune and relevant information about 
their state of health.  
Although the majority of the ICTs’ promoters in health advocate for positive 
benefits originated from the implementation of such technologies in the health sector, a 
uniform international consensus about the potential benefits and savings of what can be 
achieved in the health sector unfortunately does not yet exist (Brailer, 2008; Chaudhry et 
al., 2006; Hill et al., 2007). This is because the controversy relegated to ICTs lies not only 
in the qualification of the benefits, but also in its quantification caused by the inexistence of 
a globally accepted form of measurement. 
Regardless, the rapid development and integration of ICTs and their consequent 
effect on the health sector have necessitated the replacement of the such antiquated terms as 
‘medical informatics’ (the processing of medical data by computers) and ‘information 
processing; having presently evolved to ‘information communication’. The common 
denominator of all these technologies is data digitization, which enables the processing and 
dissemination of patient data in the mode to which we have become accustomed. Through 
these advances, the use of the ICTs for data collection, analysis and modeling, ultimately 
yield a more important role than ever. Despite all the advantages associated with the 
introduction of the ICTs however (reduction in medical errors, improvement in health 
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efficiency, significant reduction in storage space and more share ability of medical 
information), currently, the use of these technologies in health sector still remains 
somewhat limited. 
Despite the success of digitalization in other information intensive industries, the 
industry itself has not been as dynamic or open to change as much of the health data 
continues to be processed manually and X-ray images that are sent by regular mail. These 
techniques are certainly more expressive in diagnostics (computed tomography and 
magnetic resonance imaging, for example) than in process organization. A continued 
reliance on these means ultimately serves as a barrier that prevents greater proliferation of 
ICTs. In the next section, we will analyze in more detail the obstacles that the ICTs face. 
 
 
2.4 The Limited Use of ICTs 
 
Despite the fact that the field of health economics is built on pillars of knowledge 
and information, there is a technological lag in the implementation of ICTs compared with 
other similar industries with these same characteristics. The limited use of ICTs in the 
medical area is not something specific to electronic health records but an example of the 
limited use of ICTs in health care more generally.  The health industry invests only about 
2% of its revenues in Information Technologies compared with 10% of other information-
intensive industries, indicating an under-exploited and under-appreciated use of ICTs in the 
health sector (The Economist, 2005). Such a situation is especially due to the existence of 
legal, operational, cultural, attitudinal, and financial barriers in the health sector to the 
implementation and use of such technologies. 
On one hand, the existence of several laws with the aim of promoting privacy of 
patients can jeopardize the system, due to the tradeoff between privacy of patients and 
increasing interoperability between different service providers. Conversely, the absence of 
a law that simultaneously standardizes the procedures in the treatment of medical 
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information and clarifies the liability of providers in the disseminated information can also 
be a seen as a legal barrier in the adoption of the ICTs (Hill and Powell, 2009). 
The operational barriers arise mainly in the absence of an electronic language and 
uniform procedures amongst service providers, which makes the improvement of internal 
processes and communication between them and between physicians and patients, very 
difficult (Hill et al., 2007). The fact that, an individual who acquires the technology is not 
the same one that will use it creates space for the emergence of conflict situations around 
the adoption of the same by the clinicians. In this respect, the change of health 
professional’s mentality, by the explicit demonstration of the benefits that arise from such 
adaptation to their own practice (reducing medical errors, less waste of time), helps 
improve efficiency, cost savings and greater access to information that the ICTs will 
provide. Moreover, these will help erode or eventually overcoming one of the main 
obstacles to the adoption of the ICTs. However, training health professionals to properly 
deal with new technologies is another challenge that must be faced. 
The slow adoption of ICTs in the healthcare area is also due in large part to the bias 
of incentives to adopt the these technologies themselves, resulting from the fact that health 
sector is not inserted into a real competitive market, specifically as payment is respectively 
diffused between patient, employer and insure. This creates an enigmatic state in which the 
patient does not have a simplified conception of the costs involved in receiving medical 
care. 
Sometimes, the incentives given to services providers are not the most appropriate 
in promoting the adoption of ICTs, aside from being frequently seen as a misalignment of 
incentives between those who must pay for eHealth and those who are the direct 
beneficiaries (Brailer, 2008). The indexation of health professional’s payment to billable 
events (operations and medical consults, for example) creates a disincentive in the use of 
techniques that can reduce medical errors and secondary complications (Hill and Powell, 
2009). Furthermore, the health sector is not included in a genuinely competitive market (a 
significant percentage of the institutions in medical care are nonprofitable institutions), 
which generates some inertia in the adoption and use of ICTs as a privileged mean to save 
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resources. If patients support all the costs of healthcare received, and assuming that 
economic agents are rational, patients would thereby require medical services with good 
quality at reasonable prices. Thus, medical care providers (hospitals, clinics and private 
doctors) would have more incentive to adopt cost-reducing technologies that would allow 
for the maximization of services’ quality in order to become more competitive. 
Avoiding the isolation of medical providers from the market forces can also 
possibly reduce the technological lag between medical sector and others information and 
communication-intensive sectors inserted in a competitive market, transforming ICTs 
adoption, which would succeed in lowering costs. The ‘first-mover disadvantage’ is another 
kind of problem that blocks the implementation of the ICTs. Presently, the first healthcare 
entity to adopt any kind of ICTs can only maximize the value of his investment when other 
entities adopt the same kind of technology – network Effects (a large majority of the ICTs 
exhibit network effects in the sense that give a utility to their users that increases with the 
number of other users of that technology). Only when ICTs’ adoption reaches the 40-50% 
threshold of exposure will market forces take over because health ICTs will become a 
requirement for doing business (Brailer, 2008). 
The high costs associated with the implementation of ICTs are also a barrier for the 
technology’s diffusion. This logic can be traced back to a statement by Feldstein (1971): 
“…new and sophisticated equipment has been a crucial factor in rising medical care 
outlays. New technology (automation) in medicine, unlike that in other industries, has 
unfortunately tended, on the whole, to be cost-rising rather than cost-saving. The initial 
expense for the new equipment and its installation is often high…Once the equipment is in 
place, operating costs, including the cost of the highly trained personnel usually required, 
can be substantial” (Watson, 1977, pp. 4). 
According to Cutler and McClellan (2001), the only way to understand such barriers 
involves the comprehension of the different forms in which technology affects the health 
system – the treatment substitution effect and the treatment expansion effect. Generally, 
new technologies are introduced in health sector with the aim to replace old technology 
previously used to treat certain conditions, i.e. the treatment substitution effect. In turn, the 
second effect is related with the possibility offered by the new technologies in the treatment 
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of a wider range of people that were not covered by the old technology. For example, 
cataract surgery was performed much more frequently as the procedure improved over time 
(Cutler and McClellan, 2001). 
 
 
2.5 Managing the adoption of ICTs 
 
From an economic point of view, the implementation of ICTs will also be 
advantageous if they simultaneously allow for the reduction in administrative and operative 
health services costs and allow the emergence of new delivery models of medical service, 
which help encourage the innovation and the generation of savings in resources). In 
economic terms, the implementation of ICTs in healthcare will be profitable if their 
benefits, as often measured by the Quality-Adjusted Life-Years (QALYs), outweigh a 
given level of costs. The QALY is a measure of the burden of disease, including both the 
quality and the quantity of life lived. It is based on the number of years of life that would be 
added by the intervention. 
In order to assess whether the benefits from the implementation of new technologies 
in health outweigh the costs, Cutler and McClellan (2001) analyzed the introduction of 
ICTs in five specific conditions (heart attacks, low-birth weight infants, depression, 
cataracts, and breast cancer) concluding that, “the estimated benefit of technological change 
is much greater than the cost” (pp. 11) – such conclusions do yield profound implications 
for public policy undertaken in health area. 
On a broader scale, some countries such as the United Kingdom and Australia, have 
founded institutions with the sole aim to economically evaluate the adoption of certain 
technologies (not only ICTs but also myriad drugs) in health. By this same vein, the 
National Institute for Health and Clinical Excellence (NICE) was created in United 
Kingdom and the Pharmaceutical Benefits Advisory Committee (PBAC) appeared in 
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Australia, both utilizing cost-effectiveness analysis as a mean to evaluate the possible 
implementations of the ICTs and drugs. 
Created in 1999, the NICE is an independent health organization of the NHS in 
England and Wales, responsible for providing national guidance, based on cost 
effectiveness and efficacy analysis of the situations in question. Its guidance embraces 
clinical practice (in the evaluation of the most appropriate treatment, for example), the use 
of health technologies within the NHS (such as, in the use of new and existing medicines) 
and guidance for public sector employees on health, with the aim to promote good health 
and prevent and treat diseases. 
The PBAC is an independent expert body appointed by the Australian Government, 
constituted by doctors, health professionals, health economists and consumer 
representatives. Its primary role is to recommend new medicines for listing on the 
Pharmaceutics Benefit Scheme. When recommending a medicine for listing, the PBAC 
takes into account the medical conditions for which the medicine was registered for use in 
Australia, its clinical effectiveness, safety and cost-effectiveness (“value for money”) 
compared with other treatments. 
In general terms, the creation of these entities was based especially in the pursuit of 
value for money in healthcare, given the largest issues in the health sector are 
understanding how governments can get more value for what is spent and how they can get 
a more competitive market for healthcare services. NICE has a range of responsibilities of 
which the best known are the guideline ‘products’, covering both guidance on the use of 
individual health technologies and clinical guidelines on medical conditions (Towse and 
Pritchard, 2002). 
The cost-effectiveness analysis is the criteria used by this kind of institutions to 
guide the adoption of new and existing technologies. This analysis includes not only the 
total costs of implementation (both financial and in terms of resources) but also all cost 
savings that accrue through the adaptation. It is the privileged tool used to allocate scarce 
healthcare resources based on the costs and benefits of available medical technologies 
(Anupam and Philipson, 2007). 
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If a technology, after being created, has a low cost-effectiveness (static benefits do 
not outweigh the costs), it will not be implemented. According to Anupam and Philipson. 
(2007) “technologies are most cost-effective when the associated consumer surplus – the 
benefits to consumers net of the price paid – is also large. Consumer surplus concerns the 
difference between benefits and costs, versus cost-effectiveness criteria, which concern the 
ratio” (pp. 698). 
Although recent studies (have confirmed that the implementation of ICTs in 
information intensive industries allows significant gains in data sharing with high levels of 
privacy and security, facilitating the information’s organization does not preclude the 
existence of key barriers impeding a more widespread use of ICTs (Brailer, 2008; 
Khoumbati et al., 2006; Miller et al., 2005). Hence, the acceptance and the accessibility to 
the new technologies are essential to enhance the demand and use of new equipment and 
services available to the medical community. According to the World Health Organization 
(2006), the use of ICTs in the health sector not only refers to its technological aspect, but 
also to the means necessary to achieve certain results. 
Despite the technological lag that has occurred in the health sector during the last 
years, the medical community has continued to undergo an increasing adoption of ICTs in 
the medical field. This phenomenon is due in part to the broader use of the Internet and 
browsers by patients with the aim of acquired medical information about their respective 
conditions. Such empowerment of patients, equipped with easily accessible information on 
health, disease prevention and disease management, has collectively led medical 
professionals to recognize ICTs’ integral role in the delivery of reliable healthcare. 
However, in order to verify the optimization in the use of new technologies with the 
aim of improve the delivery of healthcare, it will still be necessary to address a series of 
challenges in the future. According to Haux (2006), the creation of institutional health 
information system strategies will be required, at both the national and international levels, 
covering the all aspects of the health system. That is to say there remains a need to 
consolidate the legislation in this area and establish a close collaboration between health 
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professionals, public and private sectors, and government. This would effectively allow for 
the reduction of costs through the sharing of resources between institutions. 
Moreover, the provision of worker-specific skills, in regards to utilizing ICTs, will 
be another possible challenge to be addressed in the future. It will be necessary to provide 
some skills and technical training in order to facilitate the use of ICTs and reduce the 
reticence demonstrated in the adaptation of such technologies in the sector. Alternatively, 
the diffusion of ICTs could also lead to problems of compatibility and interoperability 
between systems and technologies, which would imply the development of adequate 
infrastructures to resolve such technical challenges (Lèger, 2000). Regardless, proponents 
of ICTs are hopeful that greater volumes of personnel familiarized with eHealth services 
will correlate to an increased demand for these kinds of services. As such, in the future, it 
will also be necessary to invest in more infrastructures and equipment to ensure, not only a 
proper response to this growing demand (telemedicine, for example), but also to enable the 
cessation of information gaps and poor communication between medical personnel and 
institutions. Finally, the more intensive reliance on new technologies in the treatment of 
medical information will also require greater attention to security to ensure a higher level of 
patients’ privacy and confidentiality. 
It is important to note the effective limits potentially reaped through the adoption of 
new technologies – while ICTs are ultimately designed to provide better quality of life for 
patients, they are not enough by themselves to fully guarantee a truly effective assistance to 
the patient. Consider an example where the psychological state of a patient is worse than 
his physical state, requiring human care treatments that ICTs simply are not equipped for. 
The healthcare sector’s should embrace a greater reliance on advanced technological 
resources due to its benefits, though nevertheless health specialists should be careful about 
the risk of mechanization of the healthcare, always mindful of the benefits of human 
contact. 
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2.6 Conclusion 
 
Health economics is the coalescence of a global discipline, associated with the 
developments and progress observed in medicine in spite of a counterbalance of high costs 
associated with their practice that have instigated significant increases of health spending as 
a share of gross national product in developed countries (Barros, 2009). Since Mushkin’s 
paper published in 1958, the literature about health economics issues has become far more 
widespread and embraced in the academic and economic community via countless 
scientific publications and tireless research. The evolution of the Health Economics has led 
to adopt a very ‘medical’ model of health, in which the predominant production input for 
health is health care (Edwards, 2001). In spite of the first notion of Health Economics 
division into two fields of research that has appeared in Mushkin (1958), Arrow (1963) and 
Grossman (1972 a and b)), only in 2001 the distinction between healthcare economics and 
health economics was public recognized with Edwards’ paper (2001), a key precipice. 
The wave of innovations verified in the health sector during the past few decades, 
such as the introduction and use of health technologies and the emergence of new drugs, 
and medical equipment, to name a few have created the need to invest in new 
processes/infrastructures. Moreover, these innovations collectively help increase the quality 
of care in a more efficient and effective way, including the implementation of techniques 
such as eHealth.  
Despite the role played by eHealth in terms of economic efficiency and cost control 
the use of the ICTs in health sector still remains limited in several health areas, due to the 
existence of some barriers, inherent to the sector. Notwithstanding these issues, the study 
developed by Cutler and McClellan (2001) concluded that, in some specific conditions (as 
heart attacks, low-birth weight infants, depression and cataracts), “the estimated benefit of 
technological change is much greater than the cost”. 
As such, the future will aim to ensure the best use of ICTs in health sector, while 
also addressing the specific challenges such as the creation of institutional health 
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information system strategies and a national and/or international communication networks, 
the harmonization of the healthcare legislation, the provision of specific skills to the health 
workers, and finally the enhancement of the compatibility and interoperability between 
systems and technologies, among others. 
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3.1 Introduction 
 
Over time, the period of rampant growth in healthcare spending attracted the 
attention of several leading health economists, organizations, and policymakers, whose 
chief concerns were to address issues related to healthcare expenditure’s cost-containment 
and cost-effectiveness. Indeed, within just two decades, the impact of health on Gross 
Domestic Product (GDP) effectively doubled across countries, which raised a series 
questions about the reasons and sustainability of such growth. For example, between 1960 
and 1980 the weight of healthcare spending in GDP in Iceland, Ireland, Japan, Norway, 
Spain and USA increased from 3%, 3.7%, 3%, 2.9%, 1.5%, 5.1% to 6.4%, 8.2%, 6.4%, 7%, 
5.3%, 9%, respectively (OECD Health Data, 2012). 
With an aim to combat the increasing pressure exerted by the mounting trend of 
healthcare expenditure against national budgets, some countries, namely in the OECD, had 
moved to adopt a number of healthcare reforms, such as the introduction of prospective 
payment systems and top-down budget controls, downsizing in the hospital sector and 
decreasing the number of healthcare personnel, the combination of cost-containment 
strategies with long-term structural changes to improve value-for-money in healthcare, the 
shift of healthcare expenditures to private financing; strategies to control utilization, the 
imposition of budget constraints on providers, requiring individuals to bear a greater share 
of their expenditures, through an increase in copayments; demand and supply-side cost 
sharing, the separation of the role of supplier and buyer, the alignment of incentives with 
objectives through contracts, the decentralization of decisions, the limitation of budget 
transferences, the control of prices and wages, among others (Docteur and Oxley, 2003; 
Imai, 2002; Oxley and MacFarlan, 1994). 
However, despite the implementation of such reforms, presently we continue to 
observe a significant growth trend in healthcare expenditure, not only in relative terms but 
also in absolute terms, as shown in Figure 3.1. 
CHAPTER 3 
 
30 
 
Figure 3.1. Health Expenditure as a share of GDP 
 
In this figure we compare healthcare expenditure as a share of GDP in 1975 and 2010, in different 
OECD countries, using OECD Health Data (OECD, 2011). As it is possible to see, the percentage of 
healthcare expenditure as a share of GDP increased from 1975 to 2010. 1: 1980; 2: 1990; 3: 1999; 4: 
1988; 1997; 6: 1995. 
 
 
Notwithstanding this recent trend, real growth in healthcare expenditure per capita 
began in the 1950s, coinciding with a period of economic expansion and social progress 
across developed countries. This process led to the implementation of social reforms in 
order to ensure more benefits to workers, specifically broadening their respective access to 
healthcare. Moreover, other factors seem to have contributed to the increase in healthcare 
costs, including demographic factors, the re-organization of healthcare system, and 
technological and scientific progress, among others. 
Amidst this context, some studies started to appear in the 1970s that catalogued the 
analysis and consequent influence exerted by certain measurable variables, such as 
inflation, ageing, medical visits, and number of beds, on healthcare spending (Klarman et 
al., 1970). By the 1990s, an expansion of the literature had widened to the contemplation of 
effects of certain behavioral variables and other non-directly measurable variables – some 
studies used the theory of growth accounting and the residual approach to indirectly 
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measure one of the most intriguing paradoxes witnessed across health spending, i.e. the 
impact of technological innovation on healthcare costs (Newhouse, 1992; Peden and 
Freeland, 1998). 
In spite of the importance of these works, their utilized methodologies underscore 
certain shortcomings, namely that there is a compound risk of confounding technological 
innovation in health with other factors that are not fully captured by the regression, 
cautioning against the final interpretation of the results. 
To allay these prior concerns, the purpose of this paper is to determine the main 
factors that, over the last few decades, have contributed to the increase in healthcare 
spending, explicitly focusing on the impact of technological innovation in the healthcare 
sector. Relying on multiple imputation techniques in order to overcome the problem of 
missing data, we add to this literature by using a panel data analysis, which we are aware, 
has only been used by Gerdtham et al. (1998) and McGuire et al. (1993). Moreover, we 
will augment the existing literature by directly analyzing the impact of technological 
innovation through the creation of a healthcare technological composite index that are able 
to reflect the role of new technologies in healthcare sector. 
According to our results, ascertained by the composite technological index, we find 
that technological innovation has yielded a positive impact on total healthcare expenditures 
per capita. This suggests that the introduction of new technologies contributes to the 
increase in healthcare expenditures observed during the last few years, which is consistent 
with the results in the literature. Moreover, by analyzing the non-linear effects of cost 
increases, we can also conclude that this rise in healthcare expenditure per capita that is 
driven by technological innovation exhibits diminishing returns, eroding with volume. In 
addition, based on the results of our study, we were able to find that most of our sample of 
presently developed countries has passed a key inflection point, allowing them to 
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efficiently save resources with technological innovation
1
. This is a new result in the 
existing literature. 
 
 
3.2 Literature Review 
 
“I believe the bulk of the residual increase [in rising health 
care costs] is attributable to technological change, or what might 
loosely be called the march of science and the increased capabilities 
of medicine.”   
Newhouse (1992, pp. 11)  
 
Real growth in healthcare expenditures per capita is not a recent phenomenon. This 
long-term trend began as early as the 1950s, coinciding with a period of robust economic 
expansion and social progress across a cascade of developed countries as well as the 
implementation of social reforms that ensured healthcare benefits to workers. 
Over the years, other factors seemed to have contributed to this increase, including: 
technological and scientific progress, demographic factors such as the increase of 
population size and average life expectancy, the increase in female labor-market 
participation, the increase in the number and the price of medical procedures and staff, 
higher consumption of new drugs, the increase in health insurance or health system 
coverage and the re-organization of health care systems (reimbursement system, contract 
system, or integrated systems). 
                                                          
1 
In this paper, the concept of efficiency translates the maximization of population health status given the 
minimum amount of resources; both in terms of money, time, materials, and medical staff. 
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In the reimbursement system, providers receive retroactive payments for services 
supplied. The contract system involves an agreement between third-party payers (insurers) 
and healthcare providers, with the goal to have greater control over total funding and its 
distribution. On the other hand, in integrated systems the same agency controls both the 
funding and the provision of health services (Gerdtham and Jönsson, 2000). 
Despite the verified slowdown in the share of GDP accounted for health in the 
1980s, quite possibly as a result of reforms implemented especially in the 1960s by 
different countries, the growth of healthcare spending continues to be a recurring problem 
in the developed world to this day. Explaining the steady upward spiral of healthcare 
expenditures has been a popular and pressing theme on government researchers’ agendas 
for several decades. 
Aiming at understanding and restricting such growth, 1960s witnessed the 
appearance of the first studies of the different factors driving the growth of health 
spending.. The earliest studies performed to address this topic were done by Abel-Smith 
(1967), Feldstein (1971), Freeland and Schendler (1983), Fuchs (1972), and by Klarman et 
al. (1970), primarily based in the analysis of the influence exerted by certain measurable 
variables, i.e. inflation, ageing, medical visits, number of beds, in healthcare spending, not 
considering the observed effect of behavioral variables. These include for example, 
expectations and supplier induced demand, which theoretically affect the demand for health 
services, and consequently the level of healthcare spending. 
The consideration of immeasurable variables only appears with the emergence of 
some more recent works done by Barros (1998), Cutler (1995), Newhouse (1992), and 
Okunade and Murthy (2002). These studies distinguished themselves by the fact that they 
made attempts to disaggregate healthcare spending growth, not only directly through 
measurable variables, but also through variables that allow translating the impact of 
behavioral factors in the demand of healthcare and the inclusion of phenomena that is not 
directly measurable, such as technological innovation. In this way, they factored in the 
estimates of some variables that were representative of all important behavioral factors. 
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Despite the prevailing literature that studies the determinants of healthcare cost 
growth utilizing different methodologies to analyze this same problem in question, these 
studies do share some conclusions that have been consistently pointed to the drivers that are 
deemed the most important. For example, authors agree that the effect of income on health 
expenditure is both positive and significant – an aging population plays only a minor role in 
increasing costs, the existence of ‘gatekeepers’ helps to reduce costs despite been usually 
insignificant, public sector provision of healthcare services increases health expenditure, 
and technological change is the most important driver of spending increases over time 
(Gerdtham and Jönsson, 2000). 
To understand these conclusions in greater detail, in the next sections we will 
separately analyze the most important variables/factors, i.e. economic, demographic, social, 
behavioral and institutional variables that are present in the recent literature about the 
theme. 
 
3.2.1. Aging  
Population ageing is a sign of economic and social progress, however in developed 
countries this can also be a sign of increase in healthcare spending. According to Reinhardt 
(2003), people aged older than 75 years have a higher probability of requiring medical 
attention, incurring medical costs nearly five times higher in comparison with people aged 
25 to 34 years. Or, according to Oxley and MacFarlan (1994) “persons aged over 65 
consume, on average, roughly four times as much healthcare as those below 65”. As such, 
as the healthcare spending generally increase with age and people live longer, it is natural 
to conclude that healthcare spending consequently grows with the aging of population. The 
increase in the proportion of elderly people in the population tends to increase the demand 
for health services, with the others things constant (Fuchs, 1972). This vision is defended 
especially by cross-sectional studies. 
Even though some econometric studies have found jointly positive and significant 
influences of aging on healthcare costs (Blomqvist and Carter, 1997; Breyer and Felder, 
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2006; Hitiris and Posnett, 1992; Jönsson and Eckerlund, 2003; Lubitz et al., 1995; Roos et 
al., 1987; Schulz et al, 2004; Seshamini and Gray, 2004a, 2004b), there are still others that 
estimate a residual influence with insignificant results (Barros, 1998; Gerdtham et al., 
1992a, 1992b and 1998; Gerdtham and Jönsson, 2000; Hogan et al. 2001; Hoover et al. 
2002; Leu, 1986; Lubitz and Riley, 1993; Oxley and MacFarlan, 1994; Spillman and 
Lubitz, 2000; Stearn and Norton, 2004; Zweifel et al., 1999). 
For example, Hitiris and Posnett (1992) found a positive and significant effect of 
age – they estimated an elasticity of health spending with respect to the share of population 
above 65 years old around 0.55, using for that the data from 20 OECD countries during an 
interval from 1960 to 1987. Blomqvist and Carter (1997) and Jönsson and Eckerlund 
(2003) arrive to the same conclusion. However, this work presented by Blomqvist and 
Carter (1997) 
 
was criticized due to the reduced number of explanatory variables used in the 
study, which may have skewed the results. 
Looking closer at the analysis done by Gerdtham et al. (1992 a, 1992 b, 1998), it is 
possible to verify consistent results regarding the effects of aging on the growth rate of 
healthcare spending, even when the databases used are not congruent. For example, in 
Gerdtham et al. (1992b) the authors estimated an elasticity of only about 0.2 using the data 
from 19 OECD countries for seven-year intervals from 1980 to 1994. In a 1998 paper, 
Gerdtham et al. augmented the number of countries to 22 as well as extending the time 
period from 1970 to 1991. Under these alternative parameters, aging did not yield any 
effect on spending. 
Under an alternative study, estimating growth rates rather absolute levels of 
healthcare expenditure using a sample of 24 OECD countries between 1960 and 1990, 
Barros (1998) concluded that aging was not a significant factor in the growth of healthcare 
spending. Additionally, Oxley and MacFarlan (1994) estimated a contribution of 0.2 
percent per year to healthcare spending in 1980 – others estimations suggest a value of 2 
percent for the expenditure incurred between 1940 and 1990 (Cutler, 1995; Newhouse, 
1992; Smith et al., 2000). 
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Accordingly with some recent studies about the determinants of healthcare 
expenditure, the effects of population age structure in healthcare spending are usually 
insignificant, i.e. less than 0.7 percentage point per year, inconclusively explaining much of 
the increase in healthcare costs over time (Ginsburg, 2008). For Banins (2003), aging 
increases spending on health until a certain age level whereby its effect subsequently 
decreases. 
As we see, the estimated value depends largely on the period under analysis and the 
others variables used. However, independently of the period in question, the contribution of 
the aging population to the growth in healthcare spending is much lower than is commonly 
perceived. 
Some studies defend that it is not age per se that enhances the increase in healthcare 
spending rather the proximity of death in one’s respective environment (Breyer and Felder, 
2006; Brockman, 2002; Felder et al. 2000; Hogan et al. 2001; Hoover et al., 2002; 
Levinsky et al., 2001; Lubitz and Riley, 1993; Lubitz et al. 1995; Mcgrail et al. 2000, 
Moïse and Jacobzone, 2003; Roos et al., 1987; Schulz et al., 2004; Serup-Hansen et al., 
2002; Seshamani and Gray, 2004a, b; Spillmann and Lubitz, 2000; Stearn and Norton 
2004; Zweifel et al. 1999). Under this logic it is this phenomenon that determines the 
positive relationship between spending on health and aging, given that increased proximity 
to death augments the probability of becoming ill – a state where medical care is at its 
highest. It is important to note that this finding is more common in longitudinal studies. 
Despite the possible predisposition of an ageing population to incur higher levels of 
healthcare spending, according to the majority of studies, there are several others factors 
that play an even more important role in driving up healthcare spending. Furthermore, the 
implications of population projections should be treated cautiously due to the fact that the 
impact of aging on spending will depend, amongst other things, the intensive utilization of 
healthcare services, forms of elderly care and technology (Oxley and MacFarlan, 1994). 
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3.2.2. Income  
During the last few decades, real income per capita has significantly risen, as well 
as the demand for healthcare itself. Acute or widespread rises in income can also change 
the patterns of overall consumption, depending on the type of the good, keeping everything 
else constant. There are two categories of goods when we compare its demand towards 
changes in income: normal and inferior goods. In the case of normal goods, with an 
increase of income, the demand quantity of such goods increases. Moreover, these goods 
can be further divided into so-called essential goods or luxury goods. In the latter case, the 
demand quantity increases at a rate higher than the increase of income (income elasticity is 
greater than one), while in the case of essential goods demand remains almost unchanged, 
and the income elasticity is greater than zero but less than one. In turn, regarding inferior 
goods, the demand quantity decreases towards increases in income. 
Given the fact that healthcare is a seemingly desired service and generally accepted 
that the demand for healthcare increases with household’s income, there are not as of yet a 
uniform consensus about the possible elasticity or inelasticity of demand for healthcare 
with respect to income (the income elasticity of demand allows evaluating the percentage 
change in demand for healthcare as a result of a percent increase in household’s income). 
This happens because most studies developed on the topic use, as proxy of household’s 
income, the value of GDP, which can lead to estimation errors on the income elasticity of 
healthcare since this proxy doesn’t allow the isolation of household demand effects that are 
solely income-related. Estimated elasticity’s with respect to GDP can also reflect both the 
political process and institutional arrangements (Oxley and MacFarlan, 1994). 
Generally speaking, the use of GDP as an income variable relies on time-series 
analysis and international cross-section data, which often over-estimates the impact of 
income effects – in these cases, the elasticity is greater than one (Oxley and MacFarlan, 
1994). For example Gerdtham et al. (1992a) estimated a GDP elasticity of 1.33, 
significantly above one. There are other studies that arrive to the same conclusion, that is, 
healthcare expenditure increases proportionally more than GDP: Gerdtham et al. (1998); 
Kleiman (1974), Leu (1986); and Newhouse (1977). In turn, Okunade et al. (2004) 
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obtained a GDP elasticity of healthcare expenditure of around 0.6, underscoring the fact 
that healthcare is a necessity rather than a luxury (Di Matteo, 2003; Freeman, 2003; 
Ginsburg 2008; Tosetti and Moscone, 2007). 
Indeed, the problem of under or over-estimation in the elasticity of healthcare 
spending with respect to income is also prevalent whether this estimation is done based on 
micro (households expenditure) or on macro data, respectively (Docteur and Oxley, 2003). 
Morevoer, the elasticity based in micro data (for example, from the analysis in the variation 
across individual households) tends to be between 0.2 and 0.4
2
 (Andersen and Benham, 
1970; Grossman, 1972 b); Muurinen, 1982; Newhouse and Phelps, 1974; Okunade, 1985; 
Manning et al., 1987; and Wagstaff, 1986), being equal or greater than one (Getzen, 2000; 
Newhouse, 1977; Leu, 1986) using aggregate data (such as, national time series or cross 
sections of countries). 
In a 1977 study, Newhouse tried to identify the factors that determine the quantity 
of health-care services. In this article, he compared healthcare expenditure and GDP per 
capita at exchange rates, concluding that GDP was the paramount determinant of 
healthcare expenditure and that the income elasticity of healthcare exceeds one, indicating 
that healthcare is indeed a luxury good. According to data collected in 13 developed 
countries in 1971, Newhouse concluded that aggregate income explains 92 percent of the 
variance on the level of healthcare expenditure per capita between countries. 
Despite the criticisms pointed out by Parkin et al. (1987), most empirical research 
has confirmed the conclusions obtained by Newhouse’s analysis (for example, the work 
developed by: Barros, 1998; Blomqvist and Carter, 1997; Culyer, 1988 and 1989; 
Gerdtham et al., 1992a and 1998; and Leu, 1986). Alternatively, a majority of studies 
suggested that this elasticity is less than one (Oxley and MacFarlan, 1994) estimating an 
income elasticity of 0.7-0.8), while a smaller number of studies have argued that it is above 
one. If it is in fact true that the demand for healthcare increases substantially in the same 
                                                          
2
 A 10 percent increase in income increases health spending by between 2 and 4 percent. This estimated low 
elasticity may reflect the fact that generally, people with better health have higher incomes while those who 
need more healthcare are those with less income. 
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proportion as income, we cannot a priori expect that the increase in health spending is 
mostly due to rising incomes. 
Moreover, income elasticity of healthcare demand depends on other factors beyond 
the variation in income, such as the existence of insurance, the healthcare system, and the 
institutional environment, among others. For example, aesthetic surgery, physiotherapy, or 
more comfortable surroundings (private rooms) may be more sensitive to income. 
However, there is no net effect on the influence of these factors in the final value of 
elasticity, such that their role is often ignored (Oxley and MacFarlan, 1994). 
 
3.2.3. Insurance Expansion  
An overall growth in the number of insured individuals can lead to an increase in 
healthcare demand, because with insurance patients do not bear the full cost in the use of 
medical services, consequently facing a net decrease in the net price of care. This 
phenomenon happens since, according to a basic law of economics, when a given price of a 
good falls, the demand quantity increases, holding for the case of a normal good. An 
increase in "total insurance cover" is equivalent to a reduction in the price of medical care 
to the individual consumer at the moment of its delivery. Assessing the impact that this 
might have had on overall spending is difficult because there are few estimates of the price 
elasticity of demand (Oxley and MacFarlan, 1994). 
However, this trend can be seen when we analyze the behavior of the expenditure of 
other health services where insurance plays a minor role than in hospital services. For 
example, in dental services, the expenditure has risen much less rapidly over time than the 
expenditures in hospitals or on medical doctors (Fuchs, 1972). A notable example of this is 
the Rand Health Insurance Experiment, a randomized experimental study of the impact of 
insurance coverage on health spending and its decomposition at the household level, which 
estimates the sensitivity to the price paid out-of-pocket for healthcare is between -0.1 and -
0.2, indicating that the expansion of health insurance only contributes marginally to health 
spending growth (Manning et al., 1987). 
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In a Congressional Budget Office (CBO) study (2008), the expansion of insurance 
coverage verified between 1940 and 1990 contributed to 10% to 13% to the growth in 
healthcare spending during this period. Alternatively, others studies such as Aaron (1991), 
Manning et al. (1987), and Newhouse (1993), estimate a percentage between 5% and 10% 
from 1950 to 1984. 
Ultimately, despite the fact that health insurance is not an integral driver of 
spending trends, it can in fact exude its influence on delivered care – this is seen in the 
provider’s productivity and the introduction of new technologies in the health sector, which 
in turn can exert pressure on healthcare expenditure growth (Ginsburg, 2008). 
 
3.2.4. Physician-Induced Demand and ‘Defensive Medicine’  
Since the industry’s inception in developed countries, access to healthcare services 
is largely controlled by doctors and other healthcare professionals due to the sector's own 
rules and the existence of asymmetric information between patients and medical 
employees. In the health sector, doctors play a crucial role in this relationship given their 
decisions and that their behaviors affect all other interactions in the sector. When the 
workload decreases, doctors can use such power in order to induce more demand for their 
services at higher prices – supplier-induced demand. According to Newhouse (1992) and 
Smith et al. (2000), the increased expense that comes from the desire of doctors in 
maintaining or increasing their income by inducing demand for their services is not 
important enough to singularly explain the increase in health spending during the last 
decades – further conclusions are also convoluted given the difficulty in verifying and 
measuring such phenomenon. 
In capturing the influence of this phenomenon across total healthcare expenditure 
growth, there are some studies that use the number of physicians per 1.000 population 
(Gerdtham et al., 1998 and Okunade et al., 2004), while others opt for a sample of number 
of physicians per 100 hospital beds (Christiansen et al., 2006), or the number of practicing 
physicians per capita multiplied by 1.000 (Gerdtham et al., 1992a). The results obtained 
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from these studies are contradictory between them. If on the one side, Christiansen et al., 
(2006), and Gerdtham et al. (1998), find a negative effect, whereas on the other side, 
Okunade et al. (2004) find a positive effect. Gerdtham et al. (1998) find a positive effect 
when they combine the supply of doctors with a fee-for-service system. 
Despite this disparity, sometimes physicians prescribe certain exams or procedures, 
with few or no benefits for the patients, instead focusing on the overt prevention against 
possible future liabilities, which is denoted by defensive medicine. According to Reynolds 
et al. (1987), such behavior could be responsible for 1% of all medical expenditures in 
1984. 
 
3.2.5. Prescription Drugs and the Pharmaceutical Industry 
The Pharmaceutical industry emerges as another dark horse factor behind the rising 
cost in health sector despite sometimes being categorized in the technology category. This 
industry can be seen as one of the world's most research-intensive sector, verifying, in the 
last four decades, a quadruple increase in the average cost of its innovations, which has 
contributed in part for the rising costs in the health sector (Kumar and Ozdamar, 2004). For 
example, in 1993 the weight of the pharmaceutical sector on total healthcare spending was 
8.3 percent in the USA, 15.4 percent in France, 18.5 percent in Germany, and 
approximately 29 percent in Japan (Scherer, 2000). 
Despite the fact that prescription drugs probably do contribute to the reduction of 
health expenditure through the replacement of certain medical procedures such as surgeries 
(for example the case of anti-ulcer drugs), the weight of the pharmaceutical sector relative 
to the total healthcare spending and the total pharmaceutical sales per capita has increased 
over time, representing an important and growing share of health expenditures in across 
most countries (Huber and Orosz, 2003). According to the OECD (2003), in the 1990s, the 
annual growth rate of pharmaceutical expenditure was 30 percent higher than that of total 
healthcare expenditures. 
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According to Mehrotra et al. (2003), this anomaly can be explained through the fact 
that, over the years, pharmaceuticals companies have raised the prices of certain drugs, 
effectively increasing in the number of people relying on drugs due to the emergence of 
new diseases. Moreover, drug advertising is a powerful tool, which creates an artificial 
demand that can be guilty of leading people to consume more drugs, also opting for the 
replacement of older drugs by newer and more expensive ones. 
 
3.2.6. ‘Gatekeepers’ 
The gatekeepers of primary care are generalist doctors that establish the first point 
of contact between the patient and the healthcare system, cornering in this way the access 
between a hospital and specialist care. The existence of gatekeepers is more important in 
situations where there is an over-supply of physicians, checked by strong competition 
among physicians for market shares and remuneration on a fee-for-service basis (Gerdtham 
and Jönsson, 2000). 
Most the studies that include the use of primary care “gatekeepers” in the regression 
estimated coefficients that suggest lower levels of health expenditure in the presence of 
gatekeepers. For example, according with the estimation done by Gertham and Jönsson 
(2000), the countries with gatekeeper register healthcare spending 18% lower than 
countries without such entities. In turn, Christiansen et al., (2006) found a positive relation 
between gatekeeper and healthcare expenditures, whereas Barros (1998) concluded that the 
variable gatekeeper yielded an insignificant role in the control of healthcare costs. 
 
3.2.7. Technological Change 
The concept of health technology not only involves medical devices (e.g.: magnetic 
resonance imaging and computed tomography scanner, coronary artery bypass graft, etc.), 
but also advanced equipment’s used in medicine such as new procedures, processes and 
techniques, i.e. electronic medical records and transmission of information, telemedicine. 
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As such, technological changes involve not only new equipment’s and procedures but also 
improvements in existing equipment. As mentioned above, there have been copious studies 
that include pharmaceutical goods in this category, which will not be the case in this paper.  
According to Cutler and McClellan (2001), technological change in healthcare 
affects the system in two ways: through treatment substitution effect and treatment 
expansion effect. Generally, new technologies are introduced across the health sector in 
order to replace outdated technology that was previously used to treat certain conditions – 
tabbed the treatment substitution effect. In turn, the treatment expansion effect is related to 
the possibility offered by new technologies of the treatment of a wider range of people that 
were not covered by the old technologies themselves. For example, cataract surgery was 
performed much more frequently as the procedure improved over time. 
Unfortunately, these effects can also lead to an increase in healthcare costs given 
new technologies are typically more expensive and their introduction increases the type and 
the number of treated patients. Even if new procedures are less expensive than traditional 
ones, the increase in the intensity of their use can override the possible cost savings. This is 
the case of cataract surgery and the treatment for depression with selective serotonin 
reuptake inhibitors, which have cut costs but, at the same time, expanded the number of 
treated patients (Ginsburg, 2008). 
Furthermore, since these technologies are often rapidly and broadly widespread, it 
can reduce the utilization rate, consequently increasing the cost per treated patient, and in 
some cases can even be used on people for whom the benefits are smaller (Methrona et al., 
2003). Even in circumstances when technological innovation allows the use of cheaper 
medical technologies, the increase in the range of possible treatments promotes the increase 
in demand and supply (Weisbrod, 1991). For example, the new procedures that have 
emerged for the treatment of heart attacks and breast cancer are two kinds of technological 
changes that have increased spending via treatment substitution effect (Ginsburg, 2008). 
Moreover, technological progress makes it possible to avoid the death of some 
patients by curing certain pathologies that were previously fatal (at this point could also 
be discussed the additional burden brought by these people at the social security system). In 
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this way, over time, technological innovation may have also indirectly contributed to the 
growth of healthcare spending by increasing the survival rate, which also increases the 
number of chronically ill people. Indeed, these individuals can induce more costs to the 
health system because, as it is expected, they will need more healthcare services than the 
rest of the population or they will have more severe diseases, something that would have 
not occurred if they had died (Moïse, 2003). In this way, some technological advances in 
healthcare didn’t arise to as a means of preventing or curing diseases, rather to keep people 
alive, albeit at huge costs, which is the case of organ transplant, radiotherapy and 
chemotherapy (Kumar and Ozdamar, 2004). Additionally, according to Cutler (1995), even 
if new technologies or drugs are cost saving, there are other reasons that complicate the 
saving or conservation of resources. For example, certain preventive care can be given to 
everyone in the population, not only the people infected with certain disease. In some cases, 
depending on the number of people who become ill, a broad based application of a new 
technology may be preferred to prevent the spreading of a disease.  
While technological innovation in healthcare focusing especially on its importance 
in the cost increase, we cannot neglect its capabilities in the possible cost savings through 
the improvement in the overall quality, timeliness, safety and efficiency of healthcare 
service provided. For example, according to Hillestad et al. (2005), the use of electronic 
health records (a record in digital format that contains current and historical patient 
information) could produce efficiency and safety savings of $142 billion in U.S. physician 
offices and $371 billion in U.S. hospitals over the next fifteen years. 
As such, evaluating the impact of technological progress in healthcare costs is a 
necessary and complicated task due to the difficulties that arise from the direct 
measurement of aggregate technological change in the sector and the difficulty in obtaining 
a measurable proxy for technology.  
Even with these difficulties, recently several studies have emerged trying to 
measure the role of technological innovation in healthcare expenditure growth. Among 
them we can highlight the work done by Barros (1998), Cutler (1995), Newhouse (1992), 
and Okunade and Murthy (2002). Cutler (1995) and Newhouse (1992) tried to disaggregate 
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health costs growth, not only directly through measurable variables, but also through 
variables that translate the impact of behavioral factors in the demand of healthcare and the 
inclusion of phenomena that are not directly measurable. These studies include such 
measures and effects as technological innovation, revealing a common conclusion – 
technological innovation is one of the most important determinants of health expenditure 
growth. 
 “Rapid scientific advance always raises expenditures, even as it lowers prices. 
Those who think otherwise need only turn their historical eyes to automobiles, airplanes, 
television, and computers. In each case, massive technological advance drove down the 
price of services, but total outlays soared” (Aaron, 2002, pp W85). 
Newhouse (1992) uses the theory of economic growth, more properly the Solow 
model, to analyze the determinants of health expenditures in the United States of America 
(USA) in the post-war period – 1950 to 1980. In this sense, he builds a regression 
composed of variables that are capable of representing some factors known as sources of 
expenditure on health, i.e., aging, the spread of insurance, income growth, supplier-induced 
demand (number of physician), and the productivity growth in medical care. Using a 
residual approach, post-estimation, he concludes that the main force behind the growth in 
health expenditures between 1950 and 1980, was the emergence of new medical 
technologies and services and their respective adoption (the omitted variable in the 
regression). According to Newhouse (1992), technological change contributed roughly by 
half of the verified increase in healthcare expenditures, such that the others factors taken 
together only explain the remaining 50%, at most. 
Peden and Freeland (1998) utilized the same approach, operating under the 
assumption that low coinsurance levels and high research spending induce technological 
progress. With this specification, they concluded that roughly 70% and 76% of the health 
spending growth in the USA, as verified between 1960-1993 and 1983-1993 respectively, 
was due to cost-increasing advances in medical technology. However, it is necessary to 
stress that the methodology used by Newhouse (1992) and Peden and Freeland (1998) 
exhibits some tangible shortcomings with regards to the residual approach, given there is a 
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risk of confounding technological innovation in health with other factors for which the 
contribution is not fully captured (as for example education, lifestyle and environment 
questions) by the other variables included in the regression, demanding some care in the 
final interpretation of the results. 
Despite this methodological limitation, Newhouse’s work (1992) gained 
significance and importance in the area, not only for being the first one to assign a central 
role to the new technologies in determining the growth of healthcare spending, but for 
being the first to use the theory of growth to explain such phenomenon, which had 
facilitated the adoption of the idea among economists (Cutler and McClellan, 2001; 
Okunade and Murthy, 2002; Moïse, 2003). The first economists to attribute an important 
role to technology in the determination of health expenditure growth were: Aaron (1991), 
Feldstein (1971), Fuchs (1972), Goddeeris (1984 a and b), Manning et al. (1987), and 
Weisbrod (1991) (Moïse, 2003). 
A small number of studies, relying on methods other than estimating a residual, 
instead use proxies for technological innovation in health to measure the impact of 
technological innovation in healthcare costs. For example Cutler and McClellan (1996) use 
treatment for heart attack as a proxy for technological innovation because they have been 
subject to constant technological improvements over the last years. Their findings 
corroborate Newhouse’s (1992) conclusions that technology is a large determinate to cost 
growth. In 2001, they expand their work to treatments for low-birth weight babies, 
depression, cataracts and breast cancer. 
Okunade and Murthy (2002) seek to validate the conclusions obtained by Newhouse 
(1992). In order to do that, in the analysis of health spending growth verified in USA 
between 1960 and 1997, they use total Research and Development (R&D) spending and 
R&D spending specific to healthcare as proxies for technological change in health. 
According to the authors, such variables reflect the technological progress in health by the 
fact that the probability of technological innovation in the sector increases with these 
variables. The obtained results, this is, the elasticity of total R&D spending and R&D 
spending specific to healthcare with respect to health spending growth was 0.3 and 0.4 
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respectively, confirm that the technological innovation in the sector is an important factor 
in the justification of the long-term growth in healthcare spending.  
Other works have being made in the area, include a focus on specific medical 
equipment (Baker and Wheeler, 1998), surgical procedures (Weil, 1995), using as proxy for 
healthcare technology a time index variable (Gerdtham and Lothgren, 2000), or a time 
trend (Matteo, 2005). The estimation obtained by Matteo (2005) allows concluding that 
62% the increase in health expenditure is due technological change in the sector. 
According to Jönsson and Eckerlund (2003), technology is not the cause of the 
increased spending on health but rather a consequence of such increase. In turn, Newhouse 
(1992) argues “I believe the bulk of the residual increase is attributable to technological 
change, or what might loosely be called the march of science and the increased capabilities 
of medicine” (Newhouse, 1992, pp. 11). This explanation has received growing attention 
throughout the last decade amongst health economists, including notables such as Fuchs 
(1996), Okunade and Murthy (2002), and Cutler (2004). 
Invariably, we can ask ourselves why the economies continue to invest in 
developing technologies that supposedly contribute to increase spending on health. 
Furthermore, it bears understanding why expensive health technologies do not need to be 
used just because they are invented given the fact that the existence of a technology does 
not necessarily imply its use. Before being able to answer any question that may arise here, 
it is necessary to remember that there are many forces and pressures in the health market, 
not only from insurers, those also exerted from patients and health professionals (Hall and 
Charles, 2007). 
The above factors aren’t mutually exclusive – for example, income growth, 
patients’ expectations and the expansion of health insurance can encourage the 
development of more expensive new medical technologies (Peden and Freeland, 1998), as a 
result of commercial interests by the pharmaceutical sector or by companies and medical 
device makers. “With insured patients bearing little of the cost of new technologies and 
providers free to pass on these costs to insurers, the result was dramatic diffusion of new 
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technology and substantial incentives to invest in cost increasing technologies” (Cutler, 
1995 pp. 2). 
With the purpose of determining the different relationships and impacts of these 
factors on overall healthcare spending over recent decades there have emerged different 
econometric papers and methods devoted to understanding this relationship. This paper 
aims to be included in this group, which seeks to differentiate itself from the others 
especially through the use of a complete panel database method, supported by multiple 
imputation (MI) and through the construction of a composite technological index able to 
reflect the role of new technologies in healthcare sector. In the next sections we will 
describe such methodologies and characteristics. 
 
 
3.3 Methodology 
 
This paper aims to examine the effects of different variables on the amount of 
healthcare expenditure per capita – to accomplish this we created an unbalanced database 
for OECD countries during the period from 1975-2010. The database is unbalanced in that 
we do not have variables for all countries for all of the years (see Section 3.4. below for 
details). Furthermore, despite careful data collection, some variables were not available in 
their entirety for all countries. Hence, we considered it appropriate to apply a methodology 
recently developed that deals with missing data, i.e. multiple imputation. In order to allow 
the familiarization of the reader to such method we will expose below a brief explanation of 
the same. 
 
3.3.1. Multiple Imputation 
The presence of missing values, i.e. missing data for some observations, is a 
recurring problem in any dynamic real-world investigation, which can potentially 
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compromise the conclusions if the researcher does not properly take into account this fact. 
This is due in large part because most of current statistics software were developed 
assuming the existence of complete databases and were excluded from the analysis 
observations with missing values – listwise deletion (Rubin, 1987; Allison, 2000). 
Until the 1980s, most statisticians refused to work with databases containing 
missing values, seeing these datasets as something “to be gotten rid of” (Schafer and Olsen, 
1998, pp. 4). However, over time there has been a pantheon of developments or techniques 
(imputation, likelihood, and weighting approaches) and software capable of compensating 
for this problem, which has facilitated the adaptation and the work of researchers managing 
such data (Horton and Kleinman, 2007). Turning to the methodology, it is critical in 
understanding a background rational for, how to deal with missing values as it is necessary 
to decipher the latent process of absent missing values, i.e., if the missing values are 
missing at random (MAR), completely at random (MCAR) or Missing Not at Random 
(MNAR) and the pattern of missing values, monotonic or non-monotonic. 
A variable Y is “missing at random (MAR) if the probability of missing data on  Y  
is unrelated  to  the  value  of  Y,  after controlling  for  other  variables  in  the  analysis” 
and is “missing  completely  at  random  (MCAR)  if the  probability  of missing  data  on  Y  
is  unrelated  to  the  value  of Y itself  or  to  the  values  of  any  other  variables  in  the  
data  set” (Allison, 2000, pp. 3-4). In addition, the Missing Not at Random (MNAR) 
missing values are all the other cases that are neither MAR nor MCAR, but nevertheless are 
systematic, that is to say the missing values depend on the values themselves. 
Alternatively, “data set is said to have a monotone missing pattern when the event 
that a variable Yi is missing for the individual i implies that all subsequent variables Yk, k > 
j, are all missing for the individual i” (Yuan, 2000, pp.2). 
There are two generic approaches for dealing with missing data: listwise deletion 
and imputation of missing data. The latter varies through different complexities of 
methodologies from the simplest (simple imputation) to the most sophisticated (multiple 
imputation). 
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Listwise deletion restricts the analysis only to the complete observations, which 
ignores a great deal of potentially usable data. Despite this drawback, listwise deletion 
usually produces accurate estimates of the true standard errors and can be used in any 
database, irrespective of any specific computational techniques. However, it can also lead 
to larger standard errors, wider confidence intervals, and mitigated effectiveness in testing 
one’s hypotheses. Moreover, the imputation approach sees the missing values as an 
integrate part of the database, trying to impute them with values by single methods – single 
imputation (mean/ median/mode substitution, regression imputation, expectation-
maximization imputation, etc.), or multiple methods, and multiple imputation (e.g. Markov 
Chain Monte Carlo algorithm). 
Single imputation consists of replacing the missing observation for a single value 
using one of many different methods, including: replacement by an estimate that 
characterizes the sample (simple average (Haitovsky, 1968; Schafer, 1999), the median of 
the missing variable (Edwards et al., 2001) or conditional mean imputation (Little and 
Rubin, 1989); hot deck; regression (Khuri et al., 1997); maximum likelihood estimate; 
among others. This method, like listwise deletion has an inherent disadvantage of creating 
standard errors that are underestimated and test statistics that are overestimated, 
underestimating the variability of the sample because any missing value is filled only once.  
In order to overcome the problems of simple imputation, Rubin (1977 and 1987) 
subsequently Schafer (1997) and Allison (2000) developed a new method of imputation 
that seeks to deal with missing data using multivariate analysis – multiple imputation (MI). 
Through specific iterative algorithms, several imputations (N, with N≥ 2) are created for 
each missing observation (from the predictive distribution of the missing data), which, in 
accordance with certain assumptions, can produce valid statistical inference (Clark and 
Altman, 2003; Clogg et al., 1991; Little, 1992). 
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Figure 3.2. Multiple Imputation process 
 
This figure represents the three sequential phases of the multiple imputation process. 
 
As we can see in the Figure 3.2, MI involves three distinct sequential phases 
according to Rubin (1976.) First, there is an iterated generation of numbers for missing 
values based on techniques that reflect the variability between imputations. According to 
tests performed by Rubin (1987) and Van Buuren et al. (1999), the optimal number of 
iterations to obtain valid inference is between 3 and 5. From this step, N new ‘complete’ 
datasets are created and will be separately analyzed in the second phase through standard 
complete data methods, resulting from these estimates, standard errors, and p-values that 
formally incorporate missing data uncertainty. 
Finally, in the third phase, the results obtained in phase two are grouped in order to 
be analyzed and to produce valid statistical inference according to Rubin's theory (Rubin, 
1987; Rubin and Schenker, 1991). 
Suppose that we have imputed m complete datasets using an appropriate model. The 
combined estimate of each parameter is obtained according to the formula:    
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The valid standard error for each estimate requires the combination of information on 
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 The punctual estimates of parameters are obtained by the average of multiple 
imputations and standard errors are obtained through the variance of multiple imputations. 
The N created databases are subsequently analyzed using the procedures that are used in 
complete data analysis. After the creation of a ‘complete’ database, it is possible rely on the 
use of statistical software programming that is able to handle missing values, such as SAS, 
STATA, Amelia II, Hmisc, S-Plus, among others, obtaining a set of final estimates and 
standard errors. Since this method uses an iterative process in order to impute a given 
value, the estimated standard errors are more credible than those obtained by simple 
imputation, allowing for more adequate statistical inference, thereby improving the 
estimates as well as the standard errors and test statistics and increasing efficiency of the 
estimates due to the minimization of such errors (Rubin, 1987). 
Before the use of MI, it is necessary to justify or confirm if some assumptions are 
verified, especially as this method is functional under specific conditions. As such, the 
database should be MAR (which has been confirmed through the analysis of missing data 
patterns). Next, the imputation model must match the model used for analysis, whereas the 
dependent variable must also be included in the imputation model. Finally, the used 
algorithm must accommodate the necessary variables and their associations (Allison, 2000; 
Schafer, 1997). 
Despite the noted potential advantages of these aforementioned methods, there also 
exist a series of shortcomings or disadvantages, such as the underestimation of the 
variability of the imputed variable, which will generate confidence intervals narrower than 
expected, and the impossibility of taking into account the variability. Besides this, some of 
the disadvantages mentioned by Rubin (1987) comparing simple imputation and MI (more 
effort to create multiple imputations, more time to run the analysis, and more computer 
storage space for the imputation-created datasets) have been overcome due to the current 
development of computer software capable of implementing such techniques. 
During the last few years, several studies have appeared in order to test the validity 
of the MI (Ambler et al., 2007; Arnold and Kronmal, 2003; Moons et al., 2006; Shrive et 
al., 2006; Van Buuren et al., 1999; Van der Heijeden et al., 2006; Zhou et al., 2001). Most 
What are the Drivers of the Overall Increase in Healthcare 
Expenditures? A new Look at Technological Innovation 
 
53 
 
of these studies concluded that MI could indeed be efficient, since the obtained estimates 
for the imputed dataset are very similar to the obtained estimates for the complete database. 
In most of the created scenarios, MI was the best method for dealing with missing values. It 
is based on these studies that we decided to use the MI to deal with missing values, more 
specifically the Monte Carlo method based on Markov Chain (MCMC). This method aims 
to simulate multivariate distribution sets whose boundary is a stationary Markov chain that 
has the distribution that we want to find (Gilks et al., 1996). Moreover, the number of 
imputations was chosen following the recommendations by Graham et al. (2007). After 
dealing with missing values, it then becomes possible to carry out the construction of the 
composite technological index. The composition and construction of this index will be 
explained in the next section. 
 
3.3.2. Technological Composite Index 
The use of a composite technological index is proposed to address three issues: the 
lack of quantitative data able to reflect the technological level of the countries in the 
healthcare sector; the need to create a variable that could reflect such technological level, 
and the analysis of a composite indicator developed by the United Nations – the 
Technology Achievement Index (TAI). The United Nations Development Programme 
developed the TAI Index and presented for the first time in the Human Development 
Report 2001, Making New Technologies Work for Human Development. This index aims to 
measure the technological achievements of a country in four dimensions: creation of 
technology, diffusion of recent innovations, diffusion of old innovations and development 
of human skill base for technological creation and adoption. 
The variables used in the construction of the technological composite index present 
in this paper, have been collected from the OECD database, according to the available data. 
The methodology behind the construction of such variable was based on the work of Nardo 
et al. (2005), in which the weights of different variables were computed using factor 
analysis. Factor analysis aggregates indicators that are collinear with the aim to form a 
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composite indicator capable of capturing as much of common information of those 
variables as possible. The first step involves the creation of the factor loadings matrix 
through the Principal-component factor. Next the matrix is rotate and the weights are 
calculated (Nardo et al., 2005). 
In Annex A, Table A.4, we list the variables that constitute the present index with 
their respective weights. This index has two main groups of variables: group one (MRI, 
PET, GAMMA, DSA, MAM, RTE, LITH and MRIE) corresponds to healthcare machinery 
available in the country, while group two (END, DIA, FUKIDNEY, BONE, HEART, 
LIVER, LUNG and KIDNEY) represents the most innovative medical procedures of the 
past few years. By incorporating these two groups we want to replicate, such as in the 
technological composite index, the treatment substitution effect, and the treatment 
expansion effect presented by Cutler and McClellan (2001). The selected technologies were 
collected taking into account the year in which they appeared and were used.  
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3.4 Data Collection 
 
The basic statistics presented in this paper have mainly been compiled from 
different OECD sources and from the World Bank. The unbalanced dataset covers 27 
OECD countries, some of them between the years 1975 to 2010 – the descriptive statistics 
of the variables are in Table A.3 in Annex A. The set of countries in the sample is 
constituted by Australia (1975-2008), Austria (1975-2009), Canada (1975-2010), Czech 
Republic (1991-2009), Denmark (1975-2009), Estonia (2000-2009), Finland (1975-2010), 
France (1976-2009), Greece (1981-2007), Hungary (1992-2009), Iceland (1975-2010), 
Ireland (1975-2009), Israel (1995-2009), Italy (1989-2010), Japan (1975-2008), Korea 
(1981-2010), Luxembourg (1996-2009), Mexico (1991-2010), Netherlands (1975-2009), 
New Zealand (1975-2009), Portugal (1975-2008), Slovak Republic (1998-2009), Slovenia 
(1996-2009), Switzerland (1975-2010), Turkey (1976-2008), United Kingdom (1975-
2009), and the USA (1975-2009). The dependent variable used is the log of total health 
expenditure per capita in US dollars, converted at economy-wide Purchasing Power Parity 
(PPP) – THEXpc. 
In order to reflect some common factors among the countries that justify the cross-
country and cross-time differences in aggregate expenditure, we use as explanatory 
variables some socio-demographic variables: Gross Domestic Product per capita in US 
dollars, converted at economy-wide PPP (GDPpc), the proportion of population 14 years 
and under (POP14), the proportion of population over the average life expectancy (EMV), 
life expectancy at birth (LEX), the number of infant mortality, deaths per 1.000 live births 
(IM), the proportion of urban population (URB), and the unemployment rate (UNEMP). 
Alcohol consumption in liters per capita (ALCOOL) and the proportion of 
population aged 15 and over who are daily smokers  (SMOK) were included in the model 
to add lifestyle factors that show how individual health affects spending in ways not 
directly through health care spending (McKeown, 1979; Mokyr, 1997). We also introduce 
some institutional variables as out-of-pocket health expenditure, % of private expenditure 
on health (OUTP), the total pharmaceutical sales per capita in US dollars, converted at 
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economy-wide PPP (PHARM), and health expenditure financed by General Government, 
% of GDP (GOV). Finally we use our technological composite index (INDEX). The 
multiple regression analysis is present below and it is constituted by some of early-defined 
determinants and by others considered important for the explanation of the growth of 
healthcare spending in the last years. 
The model of aggregate healthcare expenditure per capita of the ith OECD country 
in year t is obtained: 
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As it can be seen from the expression above, the 27 (35) di (dt) are dummy variables 
with the value 1 for each of the 27 (35) observations corresponding to country (time), in 
order to control for any factors that are fixed within each country (and time period). These 
include two way fixed-effects models and    as an overall constant as well as a ‘country 
effect’ for each country and a ‘time effect’ for each period. 
The independent variables in the regression, except the variable INDEX, are in log 
form, so the coefficients associated with these variables represent the long-term effects of 
such variables on health expenditure. For example, it is estimated that an increase of 1% in 
   will increase health expenditure per capita by    %, ceteris paribus. In addition, the 
regression model was estimated using STATA with robust regression as the estimation 
technique (Huber, 1964). Despite the fact that Ordinary Least Square (OLS), or other 
methods of regression, have favorable properties in comparison with robust regression, the 
use of robust regression aims to overcome some limitations of traditional parametric and 
                                                          
3
 The definitions of the variables are in Annex A, Table A.3 
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non-parametric methods, allowing amongst other things, the mitigation of the effects of 
possible outliers and the preservation of the order, dispersion and symmetry of the dataset. 
In this sense, we decided to use robust regression due to the identification of outliers 
in the dataset (as we can see in the Figure 3.3, where the countries Korea (16), Slovak 
Republic (22) and Turkey (25) have either high leverage or large residual), through the use 
of classical regression diagnostics techniques adapted to imputed data, and due to the 
existence of a strong suspicion of heteroskedasticity in the data. 
 
Figure 3.3. Leverage versus the normalized residual squared for the countries in the sample 
 
 
Note: This figure was created from the dataset used in this paper to analyze the existence of outliers. It 
is possible to see that Korea (16), the Slovak Republic (22) and Turkey (25) are possible outliers in that 
they have either high leverage or a large residual. 
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3.5 Results 
 
The regression results are presented in Table 3.1– there are certain variables that yield 
a significant impact on health spending across the different regressions. This is the case for 
GDPpc, POP14, EMV, URB, ALCOOL, OUTP, IM, PHARM, GOV, UNEMP, INDEX, 
and INDEXSQ. Moreover, the determinants of health expenditure those are included in the 
regression account for almost all the variability of health expenditure per capita across a 
range of different specifications, as shown by the high estimated R
2
. 
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Table 3.1. Estimated coefficients of Fixed Effects Models (FEM) for the log of healthcare expenditure 
per capita 
Variables/Models 1 2
 
Number of 
observations 
pre-
imputation 
Percentage 
of 
imputation 
GDP per capita 0.822
a 
0.826
a 
754 - 
Proportion of population with 14 years 
and under 
0.134
a 
0.130
a 
754 - 
Proportion of population over the 
average life expectancy 
 0.016
b 
0.014
b 
731 3% 
Urban population 
 -0.256
b 
-0.286
a 
746 1% 
Alcohol consumption 0.05
a 
0.050
a 
754 - 
Tobacco consumption 
 0.001 0.013 377 50% 
Out-of-pocket health expenditure 
 -0.051
a 
-0.046
a 
400 47% 
Infant mortality -0.096
a 
-0.117
a 
754 - 
Total pharmaceutical sales per capita  0.015
c
 - 377 50% 
Health expenditure financed by 
Government 
 0.647
a 
0.644
a
 732 2.9% 
Unemployment rate
 -0.012
b 
-0.008
 
754 - 
INDEX  0.405
a 
-
 
249 67% 
INDEXSQ 
 -0.534
a 
- 249 67% 
Constant
 -0.544
 
-0.513 - - 
INDPHARM  - 0.769
a
 249 67% 
INDPHARMSQ 
 - -0.683
a 
249 67% 
R
2 0.8167 0.8148
 
- - 
F-statistic 1973.88
 
2310.85
 
- - 
F-test 0.000 0.000 - - 
F-test against 1 - FEM, C 119.65
a
 164.01
a
 - - 
F-test against 1 - FEM, T 3.05
a
 3.12
a 
- - 
F-test against 0 - FEM 73.93
a 
75.94
a 
- - 
Note: Models 1 and 2 regress healthcare spending per capita on different factors, including a 
technological composite index, using fixed effects for country and time period (fixed effects were not 
included in the table). In model 2, the technological composite index is enhanced to include 
pharmaceutical spending. a, b, c represent 1%, 5% and 10% levels of significance.  
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Through the statistical analysis (F-statistic and F-test) it is possible conclude that 
the model is statistically significant (we reject the null hypothesis that all the slopes equal 
zero). The larger the F-statistic, the more useful is the model.  This is also corroborated by 
the high value of the R
2
, which means that approximately 80% of the variance of the log of 
healthcare expenditure per capita is accounted for by the model. We found that the best fit 
for the data was a model in which fixed effects were used both for countries and time 
compared to when we used fixed effects for just time (F-test against 1-FEM, T), for just 
countries (F-test against 1-FEM, C), or when we did not use fixed effects (F-test against 0-
FEM). All the test results are statistically significant, which supports the decision of using 
2-way fixed effects models, for country and time. 
Income elasticity is lower than one (0.82), whilst also highly significant in all 
regressions and positive as expected, reflecting the fact that healthcare is a necessity rather 
than a luxury. These results are consistent with other studies including Barros, 1998; Di 
Matteo, 2003; Freeman, 2003; Ginsburg 2008; Tosetti and Moscone, 2007. Furthermore, 
the variable POP14 is positive and also significant in all regressions. The sign of this 
coefficient is consistent with theory that assumes that children between 0 and 14 years of 
age need more healthcare services than the rest of population. 
With the aim of measuring the impact of aging on total healthcare expenditure we 
created a variable that captures the ratio of people over average life expectancy for each 
country – EMV. According to our estimation, when the number of adults above the average 
life expectancy increases by 10%, we expect an increase of 0.17 percentage points in 
healthcare expenditure. The amount of private expenditure on health (OUTP) contributes to 
a decrease in health spending. This is consistent because the increase in the percentage of 
private expenditure on health represents an increase in the health price paid by the agents, 
which leads them to demand less healthcare services, contributing to the reduction of such 
expenditures. This result can also be associated with some adaptations to a reduction in 
insured people. 
The results obtained ultimately support both a significant and positive relationship 
between GOV and health expenditure. In particular, this result is consistent with the 
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emphasis of current governments on reducing the share of healthcare expenditures that are 
publicly financed because there is a contagion effect between the two variables. The higher 
the percentage of healthcare expenditure financed by the government, the higher the 
expenditure (so it will be necessary to finance an even larger amount of health expenditure, 
which will compromise more and more the solvency of public accounts). 
According to our results, there also exists a significant and negative relationship 
between infant mortality and health spending per capita. As such, when infant mortality 
decreases, health care spending increases. We also estimate the impact of the 
pharmaceutical industry through the prescription of drugs on total health expenditure, 
which has not been measured in related papers. The results suggest that the pharmaceutical 
sector has a positive impact on health-care costs, which supports the theoretical results of 
Kumar and Ozdamar (2004). 
We include URB and UNEMP to estimate THEXpc, but we find significant results 
opposite to what is expected. Although unexpected, the results obtained in these variables 
are quite consistent with the analyses elaborated by Gerdtham et al. (1992a, 1992b, 1998) 
that find a negative effect of urbanization on healthcare expenditure, and by Christiansen et 
al. (2006) that also find a negative effect of unemployment on total healthcare expenditure 
per capita.  
Relatively to the variable URB we find that urbanization has a negative effect on 
healthcare expenditure, which is difficult to explain because according to some studies 
(Kleiman, 1974) it is expected that the increase in the urbanization rate leads to an increase 
in healthcare costs due to the higher risk of contagion and lower time travel costs in urban 
areas. Some possible explanations may arise from the fact that in urban areas there is 
widespread access to improved water sources and improved sanitation facilities. These 
improve personal hygiene and consequently the quality of urban life and decrease the 
emergence of certain diseases. Moreover, a larger proportion of people with high education 
in urban areas lead to a greater awareness of positive health behaviors, through nutrition, 
diet, or exercise, for example. These collectively improve the health status of the 
population, which can lead to a lower need of healthcare services.  
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The negative effect on healthcare expenditures was obtained in the variable 
UNEMP, which was also unexpected due to the positive link that is established between 
unemployment and bad health (Christiansen et al., 2006). However, if we assume that 
unemployed people are exposed to less risk (work accidents/injuries, for example), while 
simultaneously avoiding stressful working situations, we can conclude that the increase in 
the unemployment rate leads to a decrease in the demand for healthcare. Apart from this, 
with more free time, people can apply a part of that time to take better care of themselves. 
This hypothesis is defended by Ruhm (2000, 2003 and 2005) who argues that unemployed 
people have more time for leisure healthier habits. Finally, we find that the composite 
technological index (INDEX) has a positive impact on total healthcare expenditure per 
capita. This implies that new technologies contribute to the increase in health expenditure 
verified in the last years, which is in line with the results obtained by Newhouse (1992), 
among others. 
To allow for non-linear effects of the index on health care expenditure, we included 
a variable for the index squared (INDEXSQ). However, based on the coefficient for this 
index squared, we can conclude that this increase in healthcare expenditure per capita has 
diminishing returns. More interesting, when we compare these results with the actual 
healthcare technological position of each country, we can argue that most of the developed 
countries nowadays are beyond the ‘turning point’, whereby the weight of innovation on 
healthcare costs becomes increasingly lower through diminishing returns. 
These patterns can be seen in Figure 3.4. In the first and second graphs 
corresponding to the year 1976 and 1991, all the countries in the sample are in the first 
phase. In this scenario, an increase in technological innovation will lead to an increase in 
healthcare costs. In the third graph however, we can verify that, most of the countries in the 
sample (Australia, Austria, Canada, Denmark, France, Finland, Iceland, Italy, Japan, Korea, 
Luxembourg, Netherland, Portugal, Switzerland, and USA) are on the right side of the 
turning point. This suggests that an increase in innovation will lead to efficiency gains that 
allow for a reduction in the contribution of technology to total healthcare costs. 
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Despite the initial effort of required investment, additional investments are offset 
from efficiency gains through the use of technology. This fact may lead to an increase in 
global divergence between countries with respect to technological level in the healthcare 
sector, given that countries with a lower technological levels in healthcare (Czech Republic, 
Estonia, Greece, Hungary, Ireland, Israel, Mexico, New Zealand, Slovak Republic, 
Slovenia, Turkey, and UK.) do not benefit from the resource savings that countries with a 
higher technological level benefit from, making them more prone to invest in technological 
innovation. This fact may also be aggravated by the weak capacity of the countries with a 
lower technological capacity to invest in more technologies due to the initial costs that it 
entails. 
When the variable PHARM is integrated in the technological composite index, the 
conclusions about the impact of technological innovation in healthcare spending remain 
unchanged. However in this situation, it is verified that the number of countries on the right 
side of the turning point – in the third phase – are higher than in the previous situation 
(Figure A.5 in Annex A). In other words, we find that when we account for pharmaceutical 
spending, the weight of innovation on healthcare costs become increasingly lower for more 
countries. This may happen because the access to drugs it is easier than the access to new 
medical equipment, this is, the use of drugs involves a lower investment by the countries. 
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Figure 3.4. Contribution of technological innovation to healthcare costs 
 
Note: These graphs were created from the database used in this paper and each of them shows the 
relationship between healthcare expenditure per capita and the variable INDEX, over three years 
(1976, 1991 and 2008), for the countries in the sample. According to these charts, the increase in 
healthcare expenditure per capita exhibits diminished returns fading away with its volume. In 2008, 
most of the countries were beyond the ‘turning point’ (0.38), where the weight of innovation on 
healthcare costs becomes increasingly lower. 
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Other variables were tested, such as the total number of hospital beds per million 
population, the number of doctors’ consultations per capita, the number of hospitals per 
million population, the number of professionally active physicians per million population, 
and the number of total health employment per million population. However, these 
variables were not statistical significant, which led to their exclusion from the analysis. 
Meanwhile, the study of possible time breaks in the period in question was also considered, 
however these results did not suggest the existence of any time breaks. Such conclusions 
might be due to the fact that the variables present in the regression already were captured 
endogenously, or rather because there is not any significant time break over the period 
considered. 
 
 
3.6 The Validity of Multiple Imputation 
 
To test the validity of Multiple Imputation (MI) we compared the main model with 
a model that does not use multiple imputation. It is important to mention that when we use 
multiple imputation we are unable to calculate the technological composite index because 
the proportion of missing values for the variables that constitute the index is too high, and 
hence we do not have enough observations to construct the technological composite index. 
After running the regression without using MI and without the introduction of the 
technological composite index, we find that most of the explanatory variables are 
statistically insignificant (Table 3.2). One likely reason for this is that the number of 
observations is lower than the number of observations when we use MI; with MI we have 
754 observations whereas we have 377 observations without using MI. A second possible 
reason is that we have taken out the technological index, which we believe is important for 
the model. 
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Table 3.2. Estimated coefficients of the Fixed Effects Model (FEM) for the log of healthcare 
expenditure per capita, without the use of Multiple Imputation 
Variables Coefficients 
Number of 
observations 
GDP per capita 1.08
a 
754 
Proportion of population with 14 years 
and under 
-0.29
 
754 
Proportion of population over the 
average life expectancy 
 0.01
 
731 
Urban population 
 -0.11
 
746 
Alcohol consumption 0.06
 
754 
Tobacco consumption 
 0.01 377 
Out-of-pocket health expenditure 
 -0.23
 
400 
Infant mortality 0.06
 
754 
Total pharmaceutical sales per capita  -0.03 377 
Health expenditure financed by 
Government 
 0.91
a 
732 
Unemployment rate
 -0.01
 
754 
Constant
 -3.85
 
- 
Note: In this model, we regress the log of healthcare spending per capita on different factors, using 
fixed effects for country and time period (fixed effects were not included in the table), without using 
Multiple Imputation. a represents significance at 1%. 
 
 
3.7 Final Considerations 
 
Throughout this paper we look at the amount of health expenditure as something 
high and problematic. Up until this point, it is important to analyze both the nature and 
magnitude of such concern about the amount of spending on health. We can also ask the 
question: from what point can we infer that such expenditures are high? Is there really an 
ideal amount for expenditure on health? Is this concern about the health sector legitimate? 
Are Would Health Economists exaggerating in the focus given to this phenomenon? Why 
are high healthcare costs bad? 
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 “We do not know that the current rate of medical spending growth is “too high” or 
that there are ways to slow it without doing more harm than good. We do know that there is 
more to medical care than spending, and more to medical spending than cost” (Pauly, 2003 
pp. 26). 
According to Pauly (2003), if we assume that the additional resources, which flow 
into the healthcare sector, are used to produce some good for health and welfare, then no 
kinds of preoccupation should exist around the amount and growth rate of this spending. 
However, one of the major problems surrounding the issues of health spending is the 
existent difficulty around the measurement of quantitative and qualitative return of such 
value invested. There is a problem in completely understanding truly how much effective 
spending is, i.e. how to evaluate the economically return of such investments and the 
possible contribution of this increase in spending on health. 
Alternatively, part of the increase in health spending is 'an accounting illusion’, i.e., 
it “does not involve any increase in real costs – only money costs” (Fuchs, 1972, pp. 45). In 
recent decades, there has been a ‘transfer’ into the health market sphere (where services are 
paid) of certain healthcare activities that, at first were carried out in the family circle, as the 
case of bed care and services associated with the treatment of sick and elderly. In this sense, 
there has been a substitution to formal from informal care (Gerdtham et al, 1992a), which 
occurred due to inherent factors of the development of societies, such as the increase of 
urbanization, the increased participation of women in the labor market and the 
defragmentation of families, among others (Fuchs, 1972; Maxwell, 1981; Stahl, 1986). 
On the other hand, there are also certain expenses, not only restricted to the health 
sector that will lead to a reduction in the future healthcare expenditure – spending on 
prevention measures, for example. This is prevalent in the case of anti-smoking campaigns, 
highway safety, food safety, screenings, and water sanitation, vaccines, among others 
(Orszag, 2008). In essence, these peculiarities that transform healthcare spending growth 
into a problem, reflect themselves in the excess of taxation burden, across intergenerational 
welfare, in the stimulation of the uninsured agent, in the peculiar structure of health 
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industry (essentially constituted by nonprofit organizations), and in the increase of moral 
hazard, more than is needed (Fuchs, 1972; Pauly, 2003). 
For Fuchs (1972), there is a reason for concern because in the most developed 
countries, much of the increase in health costs continues to be supported by third parties, 
i.e., a great bulk of health expenditure is financed with the recourse to public funds 
collected through taxes or compulsory social insurance contributions (Gerdtham and 
Jönsson, 2000). This situation represents a particular dilemma for two reasons: first, as the 
taxpayers have to support a reasonable part of such increase through taxes collection, the 
compensatory increase in taxes may lead to a distortion in the agents' behavior in order to 
escape this obligation. Such distortion may have a cost in the sense that tax rates have to be 
raised further, in order to the government collect the same amount of revenue (Pauly, 
2003). Secondly, the fact that governments incur a large part of that expense as well as its 
increase, threatens the solvency of public finances. This constitutes a barrier since the most 
developed countries have been consistently running budget deficits and the effort to contain 
health budgets may increase the already existing pressure on public budgets. 
Another potential problem arises from intergenerational welfare, which comes from 
the pay-as-you-go mechanism of much of the systems present in most developed countries. 
The possible debt incurred today can effectively support the increase in health costs, which 
must be paid by future generations. In addition, the fact that increased costs in health sector 
also leads to an increase in insurance premiums, which in consequence can lead to a 
reduction in the number of insured persons, brings more problems eventually to the society, 
employers, employees, governments, and patients. In general, rising costs imply an increase 
in the number of uninsured people coupled with a decrease in the access to medical services 
to the poor, elderly and persons in ill health (Bodenheimer, 2005). 
Several problems appear due to the fact that healthcare spending involves not 
only the budget of the public sector but also the budget of the private sector (households 
and insurance companies). This becomes an issue because households don’t have a great 
control over these expenses due to the urgency, fear, and pain involved in many medical 
episodes and due to the inexistence of technical knowledge necessary to face such 
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situations. According to Ginsburg (2008), these circumstances justify the fact that some 
economists are unwilling to accept the current proportion of GDP spent on healthcare as 
optimal. 
 
 
3.8 Concluding Remarks 
 
This paper considers different factors that affect healthcare spending using panel 
data and multiple imputation techniques. Through the development of a composite 
technological index and through the use of unique panel dataset that covers 27 countries 
over the years from 1975 to 2010, we found several interesting results from our analyses. 
First, a high estimated R
2
 in our econometric analyses suggests that the determinants of 
healthcare expenditure that we proposed account for almost all the variability in healthcare 
expenditure per capita that we see. 
Second, our econometric model introduces a composite technological index that has 
a positive impact on total healthcare expenditure per capita. This suggests that the 
introduction of new technologies contributes to the increase in healthcare expenditures 
verified in the last years, which is in accordance with the results obtained by the literature 
(Cutler, 1995; Newhouse, 1992; Okunade and Murthy, 2002). Our analysis of the 
technological index suggests that technology has a differential impact on costs depending 
on a country’s stage of development of technology. 
Results from Figure 3.4 further reinforce the conclusions obtained by Newhouse 
(1992) that technological innovation contributes positively to healthcare costs, given the 
fact that all countries, before 1992, were on the left side of the turning point. Moreover, by 
analyzing the non-linear effects of technology, we can also conclude that this increase in 
the healthcare expenditure per capita driven by technological innovation illustrates 
diminishing returns, fading away with its volume. 
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This allows us to conclude that more investment in technological innovation can 
efficiently save resources. Despite the initial effort of required investment, from certain 
point, additional investments are offset from efficiency gains through the use of 
technology. This fact may lead to an increase in global divergence between countries with 
respect to technological level in the healthcare sector, given the countries with a lower 
technological levels in healthcare (for example, according with our results, Mexico) doesn’t 
benefit from the resource savings that countries with a higher technological level benefit (as 
seen in the USA or Switzerland), making them more prone to invest in technological 
innovation. This fact may also be amplified by the weak capacity of countries, with a lower 
technological level or capacity to invest in more technologies due to the initial star-up costs 
necessitated. 
We also had robust findings for other variables in our model. Many of our 
conclusions, such as those regarding variables GDPpc, OUTP, and GOV reinforced findings 
in the literature such as Barros (1998) and Okunade et al. (2004). Finally, our methodology 
produced robust and interesting results, suggesting that the use of panel data and multiple 
imputation techniques may be a viable approach to the analysis of trends in health 
expenditure. These conclusions remain unchanged even when we supplemented new 
independent variables in the regression or even when we integrate the variable PHARM in 
the technological composite index (model number 2), proving in this way the robustness of 
the analyses performed (see Figure A.5 in the Annex A). However, it is worth nothing that 
one of the limitations of this study is the non-consideration of ICTs on technological 
composite index. This happens due to the inexistence of variables able to reflect the use of 
the same on the healthcare sector. 
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Annex A 
 
Table A.3. Variable names and definitions 
Variable Describe Weight 
MRI Magnetic Resonance Imaging units, total – Per million population. 0.06402 0.06232 
PET PET scanners, total – Per million population. 0.08426 0.8048 
GAMMA Gamma cameras, total – Per million population. 0.03028 0.02900 
DSA 
Digital Subtraction Angiography units, total – Per million 
population. 
0.05627 0.05148 
MAM Mammography, total – Per million population. 0.07364 0.06887 
RTE Radiation therapy equipment, total – Per million population. 0.07441 0.07377 
LITH Lithotripters, total – Per million population. 0.02428 0.02151 
MRIE 
Magnetic Resonance Imaging exams, total – Per million 
population. 
0.02805 0.02683 
END End-stage renal failure patients –  Per 100.000 population. 0.09165 0.08900 
DIA Patients undergoing dialysis –  Per 100.000 population. 0.0972 0.09220 
FUKIDNEY Functioning kidney transplants –  Per 100.000 population. 0.05794 0.05357 
BONE Bone marrow transplants –  Per 100.000 population. 0.05373 0.05019 
HEART Heart transplants –  Per 100.000 population. 0.07295 0.07040 
LIVER Liver transplants –  Per 100.000 population. 0.06361 0.05949 
LUNG Lung transplants –  Per 100.000 population. 0.06422 0.06171 
KIDNEY Kidney transplants –  Per 100.000 population. 0.06352 0.05987 
PHARM Total pharmaceutical sales per capita  - 0.04979 
This table displays the variable names, definitions and respective weights of the variables that 
constitute the technological composite index.  
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Table A.4. Descriptive statistics 
Variable Mean St. Deviation Min. Max. 
GDPpc 9.71 0.61 7.74 11.4 
URB 4.26 0.18 3.71 4.53 
GOV 1.61 0.41 -0.65 2.28 
PHARM 5.43 0.56 3.46 6.88 
EMV -3.46 0.43 -4.86 -2.38 
IM 2 0.66 0.53 4.79 
OUTP 4.23 0.37 3.12 4.6 
POP14 -1.59 0.22 -2.01 -0.91 
ALCOOL 2.21 0.53 0.13 3.02 
SMOK 3.32 0.27 2.1 3.99 
LEX 4.33 0.05 4.03 4.41 
UNEM 1.71 0.66 -1.61 2.96 
INDEX 0.30 0.079 0.00 0.778 
INDEXPHARM 0.57 0.087 0.00 0.850 
Note: This table presents the descriptive statistics of the explanatory variables. 
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Figure A.5. Contribution of technological innovation to healthcare costs, including the variable 
PHARM in the composite technological index 
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Note: These graphs were created from the database used in this paper and each of them shows 
the relationship between healthcare expenditure per capita and variable INDEXPHARM, over 
three years (1976, 1991 and 2008), for the countries in the sample for which we have data.  In 
the third graph, the countries on the right side of the turning point (0.563) are: Australia, 
Austria, Canada, Czech Republic, Denmark, Finland, France, Greece, Iceland, Ireland, Italy, 
Japan, Korea, Luxembourg, Netherland, Portugal, Slovak Republic, Slovenia, Switzerland; 
UK and USA. The countries on the left side are: Estonia, Hungary, Israel, Mexico, New 
Zealand and Turkey. 
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Chapter 4 
 
 
 
4. Rethinking the Impact of Healthcare Expenditure: 
New Empirical Evidence

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4.1 Introduction 
 
 
“We do not know that the current rate of medical 
spending growth is “too high” or that there are ways to 
slow it without doing more harm than good. We do know 
that there is more to medical care than spending, and more 
to medical spending than cost”.  
 
(Pauly, 2003 pp. 26) 
 
Over the past sixty years, the growth of healthcare spending in developed countries 
became the center of comments and discussions among politicians, administrators and 
economists in many countries. Healthcare spending has become a source of concern due to 
its absolute value and its growth rate. 
These concerns have raised some important questions regarding the amount of 
healthcare spending. At what point can we say that expenditure is high? Is there really an 
ideal level of health expenditure? Is this concern about the healthcare sector legitimate? Are 
health economists exaggerating by focusing so much on this phenomenon? Why are high 
healthcare costs bad? 
According to Pauly (2003), if we assume that the additional resources, which flow 
into the healthcare sector, are used to produce some “good” for health and welfare, then 
there should not be that much concern about the amount of spending and the growth rate of 
this spending. 
However, one of the major problems surrounding the problem of healthcare 
spending is the difficulty of measuring the quantitative and qualitative return of such value 
invested. It is difficult to completely understand how effective the spending is and to 
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evaluate the economic return of these investment and the possible contributions of these 
investments on health outcomes. 
Hence, the purpose of this paper is to determine if the concern surrounding 
healthcare expenditure is legitimate and to evaluate the return of such expenditure in 
quantitative (life expectancy) and qualitative (morbidity and disability) terms. To this end, 
we construct a new health status measure able to combine mortality and morbidity into a 
single composite indicator for a single country at a point in time. Using a large panel 
dataset of thirty OECD countries, we estimate how various socio-economic, environmental, 
lifestyles, and technological factors affect health status indicator. Our results suggest that 
the concern about the amount of healthcare expenditure per capita should not be focused 
on the total expenditure per se, but instead directed to the amount of the expenditure 
financed by the government.  
This chapter is organized as follow. Section 4.2 provides a review of population 
health status indicators. Section 4.3 presents the methodology used in the construction of 
our indicator, LEAPHS. The data, methodology, regression, and empirical results are 
presented in Sections 4.4 and 4.5. In Sections 4.6 and 4.7, we discuss the results and 
provide a conclusion. 
 
 
4.2 Literature Review 
 
Over the past sixty years, concern around the growth trend of healthcare 
expenditure in developed countries coupled with the need to evaluate the impact of such 
expenditure on a population’s health status has resulted in increased attention to measuring 
the health status of the individual and the population and to measuring the impact of some 
factors on this health status. 
Measuring population health is a vital prerequisite to creating effective public 
policy but also to assess the consequences of public interventions and/or socio-economic, 
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environmental, lifestyle and technological factors that may affect health status. A 
population’s health can be measured using essentially macro-level and micro-level 
indicators. Whereas macro-level indicators provide a broad overview of population health 
status, micro-level data can only provide information about specific aspects or dimensions 
of health. 
These health status indicators are usually used in econometric studies with the aim 
of determining the influence of some factors on individual and/or a population’s health 
status. The choice of micro-level or macro-level indicators depends on the specific nature 
of the analysis. 
 
4.2.1 Macro and Micro-level indicators 
Macro-level studies often use mortality or longevity indicators because they are 
generally good proxies for the health status of the population, as well as available for long 
time periods and for a large sample of countries. Some commonly used mortality indicators 
are mortality rates, which can be age-specific, perinatal (early neonatal or foetal deaths), 
neonatal
 
(deaths of children under 28 days of age) and infant mortality (under 1 year), all of 
which are expressed as the number of deaths per 1000 births. The most commonly used 
longevity indicator is life expectancy which can be measured at various ages, such as at 
birth, at 40, 60, 65 or 80 years old. Life expectancy is the average number of years that a 
person at the indicated age can be expected to live, assuming that age-specific mortality 
levels remain constant. Other commonly used longevity measures combine mortality and 
morbidity information, such as Disability-Free Life Expectancy (DFLE); Health-Adjusted 
Life Expectancy
 
(HALE); Quality-Adjusted Life Expectancy (QALE); Potential Years of 
Life Lost (PYLL); Disability-Adjusted Life Years (DALY); and Quality-Adjusted Life 
Years (QALY) (Cochrane et al., 1978; Joumard et al., 2008; Or, 2001; Santerre et al., 
1991). 
For example, life expectancy at birth is used as a health outcome to analyze the 
impact of medical care services and other factors (Afonso and St Aubyn, 2006; Babazono 
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and Hillman, 1994; Barlow and Vissandjee, 1999; Crémieux et al., 2005; Lichtenberg, 
2000; Miller and Frech, 2002; Nixon and Ullman, 2006; Or et al., 2005; Puig-Junoy, 1998; 
Retzlaff-Roberts et al., 2004; Soares, 2007; Spinks and Hollingsworth, 2009; Wolfe and 
Gabay, 1987). Generally, this health outcome is separately measured by gender because, 
according to several empirical studies, healthcare systems have different impacts on health 
according to gender and in particular healthcare systems can have more impact on a 
woman’s health than a man’s health (Joumard et al., 2008; Or, 2000; Silver, 1972). 
Although most authors use life expectancy at birth, some authors prefer to use life 
expectancy at different ages other than birth. For example, Miller and Frech (2002) and 
Wolfe and Gabay (1987) use life expectancy at 60; Crémieux et al. (2005) and Or et al. 
(2005) use life expectancy at 65; Shaw et al. (2002) use life expectancy at 40, 60 and 65; 
and finally Babazono and Hillman (1994) use life expectancy at 80 years. 
Some authors prefer to use infant mortality to life expectancy because the data are 
more readily available, and compared with adult mortality this indicator has more economic 
significance in terms of forgone production. Further, governmental healthcare policies seem 
to have a greater impact on mortality during infancy, and some factors such as alcohol, 
tobacco consumption, and education (factors not related to the healthcare system) have less 
impact on infant mortality than on life expectancy (Babazono and Hillman, 1994; Berger 
and Messer, 2002; Cochrane et al., 1978; Crémieux et al., 1999 and 2005; Elola et al., 
1995; Filmer and Pritchett, 1997; Grubaugh and Santerre, 1994; Hitiris and Possnett, 1992; 
Leu, 1986; Miller and Frech, 2002; Nixon and Ullman, 2006; Retzlaff-Roberts et al., 2004; 
Robalino et al., 2001; Verhoeven et al., 2007). 
Mortality rates are widely used and some authors claim they are “objectively 
measured, relatively precise and readily available” (Or, 2000, pp. 55), but they are rather 
limited as indicators of healthcare outcomes because they do not consider the quality of life 
and/or level of disability. They do not differentiate between the longevity that results in 
increased time spent in good health and, in contrast, the increased time spent with disease 
or disability (Joumard et al., 2008). 
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Due to this limitation, some international organizations, such as the World Bank 
and European Commission, have created some health status indicators that combine 
mortality and morbidity to the same indicator. The most important and most widely used of 
these indicators are
 
HALE (first designed by Disability-Adjusted Life Expectancy – 
DALE), QALE, DALY, PYLL, QALY, and DFLE. 
Some of these health measures are typically used in cost-effectiveness analysis of 
healthcare interventions to provide information about the benefits gained from such 
medical procedures and/or treatments. One example of such indicators is the QALE, which 
takes into account, usually for a given disease, the quantity and quality of the survival years 
generated by different types of medical interventions and treatments, using as a unit of 
“measure” the QALY (Masseria et al., 2007). 
QALY allow measuring the state of health of a person or population to be adjusted 
by the quality of life. According to the National Institute for Health and Care Excellence, 
this measure is calculated “by estimating the years of life remaining for a patient following 
a particular treatment or intervention and weighting each year with a quality of life score 
(on a zero to one scale). It is often measured in terms of the person's ability to perform the 
activities of daily life, freedom from pain and mental disturbance” (NICE, 2013). 
In contrast to the QALY, there is also the DALY. While QALY are a positive 
concept (healthy life years gained), DALYs represent healthy life years lost: the sum of 
PYLL lost due to premature mortality and the years of productive life lost due to disability 
(YLD) (WHO, 2013 b). One QALY (DALY) is one gained (lost) year of healthy life. 
Besides being used as a health macro-level indicator per se, DALYs are also used as 
an integral part of another important macro-level indicator – the HALE. 
HALE represents the average number of years that a person can expect to live in 
"full health" by taking into account years lived in less than full health due to disease and/or 
injury” (WHO, 2013 a). In the HALE the years spent in unhealthy states are subtracted 
from overall life expectancy and weighted according to the severity of the unhealthy state. 
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The difference between life expectancy and HALE corresponds to the equivalent person-
years of life lost due to disability. 
DFLE is similar to the HALE. However, the indicator is not adjusted by the severity 
of the illness (Joumard et al., 2008). 
PYLL is a “summary measure of premature mortality, which provides an explicit 
way of weighting deaths occurring at younger ages, which are, a priori, preventable. The 
calculation of PYLL involves summing up deaths occurring at each age and multiplying 
this with the number of remaining years to live up to a selected age limit” (OECD, 2012). 
“DFLE is the average number of years an individual is expected to live free of disability if 
current patterns of mortality and disability continue to apply” (OECD, 2001). 
Due to the lack of time series data and rare country coverage of these indicators, 
there are not as many studies that use these kinds of indicators compared to the other 
macro-level indicators. Some studies that use the DALE include Miller and Frech (2002), 
Self and Grabowski (2003), and Verhoeven et al. (2007). Or (2000 and 2001) used 
premature mortality as an outcome, instead of conventional crude death rates, represented 
by the number of PYLL. This approach is also used by Afonso and St Aubyn (2006), Elola 
et al. (1995), and Miller and Frech (2002). 
Most of the health-adjusted life expectancy measures presented above are 
essentially based on micro-level health measures, because micro-level health measures 
include detailed clinical, behavioral, and personal information, using disease-specific 
measures such as blood pressure, eyesight, observed ability to carry out activities of daily 
living (ADL), body mass index, the Short form 36-item Health Survey (SF-36), the EQ-5D 
(Euroqol, 2013), and the Health Utility Index (Dolan et al., 1995; Torrance, 1986). 
SF-36 is a health-related quality of life measure constituted by 36 questions “which 
measure eight multi-item variables: physical functioning (ten items), social functioning 
(two items), role limitations due to physical problems (four items), role limitations due to 
emotional problems (three items), mental health (five items), energy and vitality (four 
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items), pain (two items), and general perception of health (five items)” (Jenkinson et al., 
1993, pp. 1437). 
 
4.2.2 The main determinants of healthcare outcomes 
According to the definition by the WHO (1948) health is “a state of complete 
physical, mental, and social well-being and not merely the absence of disease or infirmity”, 
which means that health is affected by a multitude of different factors not only inherent to 
the individual, for example genetics (some people have a higher probability of developing 
certain diseases); gender (men and women suffer from different types of illnesses at 
different ages), and age, but also lifestyle habits (drinking, smoking, diet); education level; 
the use of healthcare resources: socio-economic factors; and the physical environment (safe 
water and clean air). 
In light of the multidimensional nature of health, studies analyze the different 
determinants that together affect the health of individuals and communities. The first 
studies to emerge were done by Auster et al. (1969), Hadley (1982), Newhouse and 
Friedlander (1980), Silver (1972). These studies used data from the United States (USA) 
for the period of 1972 and earlier. 
For example, Auster et al. (1969) analyzed the relationship of mortality of whites 
individuals to both medical care and some environmental variables, concluding that 
environmental variables, especially education and income, are more important than medical 
care. They used age-adjusted death rates as the measure of health status. Independent 
variables include income, percent nonwhite, education, alcohol and cigarette consumption 
per capita, percent employed in manufacturing, standard metropolitan statistical areas, 
percent in white-collar occupations, females not in the labor force, and a dummy variable 
coded 1 for states with medical schools and 0 for those without. 
Using micro data from 1959 to 1962, Newhouse and Friedlander (1980) estimated a 
health production function using morbidity measures and six physiological measures (for 
example, blood pressure and cholesterol). 
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Following the same framework, Berger and Leigh (1989) and Kenkel (1991) also 
estimated health production functions with the following explanatory variables: blood 
pressure, schooling, health knowledge, self-reported health status, and other observable 
variables. 
These studies served as the foundation for the emergence of more detailed studies 
about the determinants of health status such as Afonso and St Aubyn (2005), Bhat (2005), 
Economou and Giorno (2009), Jönsson (1990), Leu (1986), Retzlaff et al. (2004), 
Schwellnus (2009), Siddiqui and Mahmood (1994), Spinks and Hollingsworth (2009), ,and 
Santerre et al. (1991). 
The variety of the health’s determinants considered in these studies is significant, 
with some determinants more important, and consequently more used, than others. Despite 
the mixed empirical results, there is a general consensus about the factors that affect the 
population’s health status. These factors include healthcare services, socio-economic 
factors (wealth, safety regulation, infrastructures), lifestyle factors (tobacco, alcohol and 
consumption of fruits, sugar, vegetables or calorie intake), environmental conditions 
(pollution), institutional factors, and finally technological factors. 
For example, to measure the impact of medical care on health outcomes most 
empirical studies use, as a proxy for the quantity of healthcare services consumed, some 
form of healthcare expenditure. Healthcare expenditure per capita is used by Babazono and 
Hillman (1994), Barlow and Vissandjee (1999), Berger and Messer (2002), Crémieux et al. 
(1999), Elola et al. (1995), Hitiris and Posnett (1992), Lichtenberg (2000), Nixon and 
Ullman (2006), and Or (2000).  
Other authors, such as Cochrane et al. (1978), Nixon and Ullman (2006), Retzlaff-
Roberts et al. (2004), have measured healthcare expenditure by using health expenditure as 
a share of Gross Domestic Product (GDP).  
Still others have used the share of healthcare spending financed by the public sector 
(Berger and Messer, 2002; Babazono and Hillman, 1994; Elola et al., 1995; Filmer and 
Pritchett, 1999; Or, 2000; Or et al., 2005), while other authors have used some specific 
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health spending components. For example, Babazono and Hillman (1994), Lichtenberg 
(2000), Miller and Frech (2002), and Shaw et al. (2002), use pharmaceuticals spending. In 
turn, Afonso and St Aubyn (2006), Cochrane et al. (1978), Crémieux et al. (1999), 
Grubaugh and Santerre (1994), Babazono and Hillman (1994), Leu (1986), Nixon and 
Ullman (2006), Or (2001), Or et al. (2005), Puig-Junoy (1998), Retzlaff-Roberts et al. 
(2004) use physical healthcare resources (as the number of hospital beds, the doctors per 
capita or the number of consultations per capita). 
Relative to socio-economic factors the most used variables are: income per capita; 
education (the proportion of the adult population that is literate – Barlow and Vissandjee 
(1999), the proportion of the population aged over 25 years with post-secondary education 
– Berger and Messer (2002), education index – Cochrane et al. (1978), the number of years 
of education – Self and Grabowski (2003), and real educational expenditures per capita – 
Grubaugh and Santerre (1994)), poverty, urbanization (the urban population as a proportion 
of the total population – Barlow and Vissandjee (1999), population density – Crémieux et 
al. (1999 and 2005), Grubaugh and Santerre (1994)), occupational status (proportion of 
white-collar workers in the total work force – Or (2000)), aging (percentage of population 
aged over 65 years – Hitiris and Posnet (1992), Wolfe and Gabay (1987)), and 
unemployment (Nixon and Ullman, 2006; Spinks and Hollingsworth, 2009). 
Most of the empirical studies in the area include the consumption of tobacco and 
alcohol in the analysis, as well as some proxies for dietary consumption (consumption of 
fruits, sugar, vegetables or calories intake) in order to grasp the influence of lifestyle on 
health status (Afonso and St Aubyn, 2006; Berger and Messer, 2002; Cochrane et al., 1978; 
Crémieux et al., 2005 and 1999; Nixon and Ullman, 2006; Puig-Junoy, 1998; Shaw et al., 
2002; and Wolfe and Gabay, 1987). 
Environmental factors are essentially represented by pollution (Nixon and Ullman, 
2006; Or, 2001; Shaw et al., 2002) and crime (Thornton, 2002). 
Some studies also include institutional factors such as: the type of health system 
(social security versus an integrated national health service – Elola et al., 1995), the 
provider payment systems at the hospital and individual level, the access arrangements 
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(gatekeeper role – Or, 2001), the public spending share in healthcare spending; the provider 
payment systems in the hospital and ambulatory sectors; the access to public medical care 
and immunization coverage (Soares, 2007), the proportion of population eligible for in-
patient care benefits under a public health scheme; the proportion of population eligible for 
ambulatory care benefits under a public scheme (Berger and Messer, 2002), the proportion 
of the population aged under 15 years; and some structural indicators (political rights, 
corruption, ethnicity – Robalino et al., 2001).  
However, it is rare for studies to include the effects of technological innovation on 
health status in their models. Sometimes, technological innovation appears as a component 
of physical healthcare resources (Afonso and St Aubyn, 2006; Or et al., 2005; Retzlaff-
Roberts et al., 2004). Only Grubaugh and Santerre (1994) included a specific variable into 
their analysis with the aim of measuring the impact of technology. To this end, they used a 
time trend as a proxy for technology. 
According to the main objective of this study and as explained above it has became 
vital to construct a new health indicator, which includes not only the quantity but also the 
quality of a population’s health, associated with a large sectional and temporal sample. In 
the next section we will be describe the steps needed for the construction of such an 
indicator. 
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4.3 The indicator – LEAPHS 
 
“…as long as we are unable to put our arguments 
into figures, the voice of our science, although occasionally it 
may help to dispel gross errors, will never be heard by 
practical men. They are, by instinct, econometricians all of 
them, in their distrust of anything not amenable to exact 
proof.”  
Schumpeter (1933, pp. 12) 
“Give me a measure – a single measure – which is as 
vulgar as GNP per capita, but not as insensitive to broader 
aspects of human life.”  
 Mahbubul Haq 
 
A historical analysis shows that, after the second half of the twentieth century, the 
world has seen a significant improvement in overall health status of the population, which 
was reflected in a significant reduction in mortality and progressive increases in longevity 
(WHO, 2010). 
Over the last century, life expectancy at birth has increased progressively whereas 
infant mortality has declined dramatically. Between 1960 and 2005, in OECD countries, 
life expectancy at birth increased by almost ten years on average, and infant mortality has 
been reduced by a factor of seven (Joumard et al., 2008). More recently, the death rates 
among the older population also began to decline. People are living longer. However, are 
these extra years of life in the same or better health, or are they spent in illness and 
dependency?  
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In order to be able to answer this question it is necessary to evaluate the quality of 
years lived, through the extension of the concept of life expectancy (mortality) to morbidity 
and disability. In this way, it is important to create an indicator that can evaluate not only 
the quantity of years lived but also the life quality of those years by adding a dimension of 
quality to the quantity of life lived.  
With the aim of answering this question different indicators associate the number of 
years lived (life expectancy) with the quality of those years, through the association of 
mortality and morbidity and disability information. Some examples of such indicators are: 
HALE; DFLE; DALYs and QALYs. 
Due to the specificity of DALYs and QALYs (they are only applied to one disease 
or treatment), lack of time series data and rare country coverage of HALE and DFLE, we 
decided to construct a new health status indicator that combines mortality and morbidity, 
through the adjustment of life expectancy to the quality of years lived – Life Expectancy 
Adjusted by Perceived Health Status (LEAPHS).  
The methodology used in the construction of our indicator, which will be explained, 
has some advantages over other health status measures. First, it is easy to explain the 
concepts that involve LEAPHS (perceived health status, life expectancy, life in good 
health) to a non-technical audience.  
Second, in clear opposition with the most used indicators (DALY, QALY, HALE 
and DFLE), one can calculate LEAPHS across many years and many countries.  
Third, the LEAPHS units and measurement are intuitive.  
Finally, perceived health status is used to calculate LEAPHS, and hence, can 
capture some factors that affect the health status of the individuals, which are not captured 
by other measures, such as education, income level, housing, marital status, employment 
and economic development as argued by Alexopoulos and Geitona (2009), Capik and 
Bahar (2008), Cox et al. (1988), Kaleta et al. (2009), Maddox and Douglass (1973), and 
Shields and Shooshtari (2001). For example, Maddox and Douglass argue “Self health 
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ratings are clearly measuring more than simple morale,” (Maddox and Douglass, 1973, 
pp.92). 
 
4.3.1 Methodology 
The construction of the LEAPHS is done in three stages. In the first stage, we 
calculate mortality risk for specific age and gender groups. This first stage is done 
following a standard method in the literature called the Sullivan method. In the second 
stage, we combine the mortality risk, calculated for specific age and gender groups with the 
perceived health status for the same age and gender groups. Morbidity is encompassed in 
the perceived health status ratings. In third stage we use the formula developed by Sullivan 
to calculate the LEAPHS, using the information collected in the previous stages. Hence, in 
this way, our indicator is able to account for mortality risk and morbidity. 
To be able to calculate the LEAPHS, the researcher needs: 
- Mortality risk data from standard life tables, available from most countries in most 
years; 
- Perceived health status data, available from most countries, which can be used to 
calculate morbidity risk. 
 We next describe the three stages of calculation of the LEAPHS. 
 
4.3.1.1. First stage of the calculation of LEAPHS 
 
For the construction of LEAPHS we resorted to a common method in the literature 
proposed by Sanders (1964) and later developed by Sullivan (1971a) – the Sullivan 
method.  The Sullivan method is used to calculate health expectancy (mortality risk) for 
different age groups, from different life tables. 
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The first life table was sketched by John Graunt in 1691, but only in 1693 appears 
the first life table based on really scientific principles elaborated by Edmund Halley. Life 
tables are statistical models that combine mortality rates at different ages, turning them into 
mortality quotients. This allows, through the association of a set of basic functions, the 
measurement of the phenomenon of mortality – the deduction of the probabilities of 
survival and life expectancy. Contrary to what happens with crude mortality rates, life 
tables have the advantage of not being affected by the age structure of the population. 
Generally life tables are calculated for each sex separately and together (Carrilho and 
Patrício, 2004). 
 
Table 4.5. Portugal, Life tables, Total 
Year Age mx qx ax lx dx Lx Tx ex 
2004 0 0.00432 0.00430 0.06 100,000 430 99,594 7,493,711 74.94 
2004 01-04 0.00037 0.00149 1.52 99,570 148 397,911 7,394,117 74.26 
2004 05-09 0.00021 0.00103 2.75 99,421 102 496,877 6,996,206 70.37 
2004 10-14 0.00019 0.00096 2.84 99,319 95 496,391 6,499,329 65.44 
2004 15-19 0.00060 0.00299 2.81 99,224 296 495,472 6,002,938 60.50 
2004 20-24 0.00098 0.00491 2.41 98,928 485 493,383 5,507,466 55.67 
2004 25-29 0.00125 0.00622 2.64 98,443 612 490,769 5,014,084 50.93 
2004 30-34 0.00164 0.00817 2.59 97,831 800 487,224 4,523,314 46.24 
2004 35-39 0.00229 0.01140 2.56 97,031 1106 482,460 4,036,090 41.60 
2004 40-44 0.00324 0.01606 2.61 95,925 1540 475,948 3,553,631 37.05 
2004 45-49 0.00461 0.02282 2.61 94,384 2154 466,764 3,077,683 32.61 
2004 50-54 0.00628 0.03096 2.60 92,231 2855 454,295 2,6109,18 28.31 
2004 55-59 0.00845 0.04141 2.59 89,375 3701 437,940 2,156,623 24.13 
2004 60-64 0.01316 0.06380 2.63 85,675 5466 415,436 1,718,683 20.06 
2004 65-69 0.02033 0.09702 2.64 80,209 7782 382,710 1,303,247 16.25 
Note: In this table we present an example of a life table for Portugal in the year 2004. Here, we have the 
year, different age groups, eg. x to x + n, where n can be 1, 5 or 10, the central mortality rate x and x + 
n (mx ), probability of dying between age x and x + n (qx), the median survival time between ages x and 
x + n for people who die in the interval (ax), the number of survivors at age x, assuming l0=100.000  (lx), 
number of deaths between ages x and x + n (dx ), the number of person-years lived between ages x and x 
+ n (Lx ), the number of person-years remaining after age x (Tx), and life expectancy in years at age x 
(ex ). 
 
 
 To use Sullivan’s method it was necessary to collect some variables in order to 
construct the mortality component of the indicator: (1) the number of survivors at exact 
age  , assuming that at age 0 the number of survivors is 100,000 (  ), (2) deaths or specific 
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mortality rates, (3) the number of person-years lived between ages   and    , (where   
can be equal to 1, 5 or 10, for example), from the abridged life table (  ), and (4) the 
number of person-years remaining after exact age  . 
This method multiplies the total number of person-years lived between ages   
and     , from the abridged life table (  ) by the corresponding severity-weighted 
prevalence of disability (  ) to calculate the equivalent healthy person years of life lost to 
disability at different ages. The number of person-years lived in good health between ages 
  and     is then calculated by separating the person-years of life lost to disability from 
the total number of person-years lived inside the age range (up to x+n). After this step, it is 
possible to obtain our indicator using the traditional method used in the calculation of life 
expectancy. 
In order to be able to combine the mortality and morbidity components we need to 
construct abridged life tables, this is, life tables with age intervals greater than one year, for 
all countries in the sample.  In our case we calculate the mortality risk for the following age 
groups: 0 to 14 years, 15 to 24 years, 25 to 44 years, 45 to 64 years, and 65 and over. In this 
way, the mortality component was obtained from the life table for all of the countries 
present in the sample.  
 
4.3.1.2. Second stage of the calculation of LEAPHS 
 
The morbidity information used for the construction of LEAPHS comes from the 
OECD Health Data 2012 – Percentage of the population, aged 15 years old and over who 
report their health to be “good” or “better” (perceived health status, by age and gender). In 
this way, our indicator adds a dimension of quality (morbidity) to the quantity of life, 
measuring the average number of years that a person can expect to live in “good” or 
“better” health. 
In the last several years, the European Union has decided to include in its European 
Community Health Indicators some health expectancies measures of disability, chronic 
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morbidity and perceived health, truly comparable between countries. This allowed us to use 
perceived health status, by age and gender, as the morbidity component. With this, we 
avoid the use of a different measure for quality of life for the different countries in the 
sample (EHEMU, 2012). 
Additionally, self-reported health, by combining the individual’s subjective 
experience of different states of health (such as of different diseases) with daily feelings of 
general well-being (tiredness, headaches, etc.), allows us to get a consistent and valid 
measure of general physical health (Davies and Ware, 1981; Mossey and Shapiro, 1982). In 
the end we have a health measure that is generally in line with the WHO’s definition of 
health, because self-reported health is highly correlated with other indicators of morbidity 
and mortality and is a stronger predictor of mortality than is physician assessed health 
(Idler and Kasl, 1991; Mossey and Shapiro, 1982; Ross and Wu, 1995). 
Self-reported health is not only a function of actual health status, but it is also 
affected by individual or population groups’ perceptions of health, and hence it is 
recommended both by the WHO and the European Commission as a reasonably realistic 
predictor of total mortality, psychological and medical symptoms, as well as return to work 
(state of health) (European Commission, 2010). Additionally, some studies show that self-
reported health is consistent with a doctor’s evaluation (Hunt et al, 1980). 
 
4.3.1.3. Final stage of the calculation of LEAPHS 
 
After we collected the two components needed to calculate our indicator, this is, (i) 
mortality risk by age groups, (ii) perceived health status by age groups (from which we will 
calculate morbidity for different age groups) we are able to construct LEAPHS, according 
to the next equation:  
       
 
  
      
  
   
       . 
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The morbidity component of the indicator appears in  , this is, the percentage of 
the population with “good” or “better” health with ages in the interval ( ;    ), and the 
mortality component is represented by   . C represents the number of age categories, 
which in our case are five. 
In this way, LEAPHS reflects the life expectancy of a specific population adjusted 
by the perceived health status of that population. Given the health status of the population 
can vary significantly by gender we construct this indicator separately for men and women 
(Haber, 1967; Jagger, 1997; Kaplan and Erikson, 2000, Sullivan, 1971 b). 
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4.4 Model, Methodology and Data Description 
 
In order to determine if the concern surrounding healthcare expenditure is legitimate 
and in order to evaluate the return of healthcare expenditure in quantitative and qualitative 
terms we use data from different OECD sources and from the World Bank. The unbalanced 
database covers 30 OECD countries, from 1980 to 2011, although some countries are not 
covered for all 31 years. The set of countries in the sample is constituted by Australia 
(1989-2007), Austria (2004-2010), Belgium (1997-2008), Canada (1994-2007), Chile 
(2000-2005), the Czech Republic (1993-2008), Denmark (2003-2009), Estonia (2002-
2009), Finland (1979-2009), France (2002-2009), Germany (1998-2009), Hungary (2000-
2009), Iceland (1998-2010), Ireland (1998-2009), Israel (2001-2009), Italy (1994-2008), 
Japan (1980-2009), Luxembourg (1996-2009), Norway (1995-2008), Netherlands (1982-
2009), New Zealand (1997-2007), Poland (1996-2009), Portugal (2003-2009), the Slovak 
Republic (2004-2009), Slovenia (2004-2009), Spain (1987-2009), Sweden (1992-2007), 
Switzerland (1992-2007), United Kingdom (1991-2004)) and the USA (1981-2009). These 
countries were selected because they are relatively homogeneous in terms of their stage of 
economic development and real per capita income. 
We build on earlier studies by using a new dependent variable – Life Expectancy 
Adjusted by Perceived Health Status – and a new explanatory variable, the technological 
composite index, to control for technological innovation in healthcare. 
The other explanatory variables were selected based on theorized relationships to 
the dependent variable, specifically on past studies that suggest various socio-economic, 
environmental, lifestyle and technological determinants that influence the health status of 
the population. The descriptive statistics of the explanatory variables are shown in Annex 
B, Table B.8 and include the minimum value, average, maximum, and standard deviation 
for each variable. 
In order to contemplate some socio-economic and environmental factors, we use as 
explanatory variables the Gross Domestic Product per capita in US dollars, converted at 
economy-wide Purchasing Power Parity (PPP) (GDPpc); total health expenditure per capita 
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in US dollars, converted at economy-wide PPP (HEpc); and the proportion of the urban 
population (URB). 
As most chronic diseases, like obesity, diabetes or cerebrovascular diseases are 
related to some human behaviors, alcohol consumption in liters per capita (ALCOOL), 
tobacco consumption – cigarettes per smoker per day (SMOK), and total fat intake in 
grams per capita per day (FAT) were included in the model to account for lifestyle factors 
that affect health. 
We also introduced some institutional variables such as health expenditure financed 
by the Government as a percentage of total healthcare spending (GOV); total health and 
social employment per million of the population (head counts) (THSE); the total number of 
hospital beds per million of the population (BED); and total public spending on education 
(as a percentage of GDP) (EDUC). Finally we use our technological composite index 
(INDEX). 
 
The “health production function” is the following: 
 
                   
  
   
                       
         
  
 
    
                                                    . 
 
The 30    are dummy variables corresponding to the 30 countries in the sample. 
The introduction of dummy variables for the countries was necessary in order to control for 
any factors that are fixed within each country. There exist some country specific 
charactersitics (such as the type of healthcare system; the method and organization of 
production; the climate, the economic, technological, demographic characteristics, and 
other national differences) that influence the performance of the healthcare system and 
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consequently the health outcomes, which are not captured by the other explanatory 
variables present in the regression. 
The explanatory variables in the regression are in log form, so the coefficients 
associated with these variables represent semi-elasticities, i.e., the increment in the average 
life expectancy adjusted by the perceived health status originated by an increase of 1% in 
the independent variable. For example, it is estimated that an increase of 1% in    will 
increase the average life expectancy adjusted by perceived health status by 
   
   
 years, 
ceteris paribus. 
 
 
4.5 Empirical Results 
 
In this section we report our empirical results (Table 4.6) by applying robust 
regression as the estimation technique (Huber, 1964). Despite the fact that Ordinary Least 
Square (OLS), or other methods of regression, have favorable properties in comparison 
with robust regression, the use of robust regression aims to overcome some limitations of 
traditional parametric and non-parametric methods, allowing, amongst other things, the 
mitigation of the effects of possible outliers and the preservation of the order, dispersion, 
and symmetry of the database. 
For these reasons, we decided to use robust regression due to the identification of 
outliers in the database (as we can see in Figure 4.6, where the countries France (10) and 
New Zealand (21) have either high leverage or a large residual), through the use of classical 
regression diagnostics techniques adapted to imputed data, and due to the existence of 
possible heteroscedasticity in the data. The regression model was estimated using STATA 
12.0. 
In order to address different statistical problems, as the existence of endogenous 
variables, we decided to estimate our regression using fixed effects instead of using 
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instrumental variables, because it is very difficult to find a obvious instrumental variables 
capable of overcome such problem. 
 
Figure 4.6. Leverage versus Normalized residual squared, for men (left) and women (right) 
 
Note: This figure was created from the dataset used in this paper to analyze the existence of outliers. 
We can see that France (10) and New Zealand (21) have high leverage and large residual. 
 
Table 4.6 presents our results for the estimation of our “health production function”. 
Here we show how our health measure, LEAPHS, is affected by the variables in, our 
model, according to gender. 
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Table 4.6. Estimated coefficients by 1-Fixed Effect Model (FEM) for LEAPHS 
Variables Women Men 
Percentage of 
variable 
impuated 
GDP per capita 2,99
b
 4,12
a
 - 
 Health expenditure per capita 3,26
a
 2,01
b
 - 
Urban population -26,44
a
 -18,56
a
 - 
Alcohol consumption -1,04 -2,05
b
 -- 
Tobacco consumption -0,20 -0,05 - 
Fat intake
 
2,15 1,99 2% 
Health expenditure financed by 
General Government 
-4,28
a
 -5,63
a
 - 
H alth and social mployment
 
-0,12 0,44 21% 
Hospital beds
 
1,09
c
 0,38 17% 
Public spending on education
 
1,00 1,53
b
 10% 
INDEX
 
-6,54
a
 -6,63
a
 70% 
INDEXSQ
 
7,06
a
 7,07
a
 70% 
Constant 139,54
a
 105,75
a
 - 
R
2 
0,982 0,981 - 
F-statistic 374,91 481,07 - 
F-test 0.000 0.000 - 
F-test against 0 - FEM 166,84
a
 189,13
a
 - 
Note: Here we regress LEAPHS, according to gender, on different factors, including a technologic 
composite index, using fixed effects for country (fixed effects were not included in the table). a, b, c 
represent 1%, 5% and 10% levels of significance. 
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4.6 Discussion of main results 
 
As the aim of this paper is to analyze the impact of healthcare spending and 
technological innovation on the health status of the population, in the next section we will 
focus on total health expenditure per capita, health expenditure financed by the 
Government, and the technological composite index. 
Through the statistical analysis (F-statistic and F-test) it is possible to conclude that 
the model is statistically significant (we reject the null hypothesis that all of the slopes 
equal zero). The larger the F-statistic, the more useful is the model.  This is also 
corroborated by the high value of R
2
, which means that approximately 98% of the variance 
of LEAPHS is accounted for by the model.  
We found that the best fit for the data was a model in which fixed effects were used 
both for countries and time compared to when we used fixed effects for just countries (F-
test against 1-FEM, C), or when we did not use fixed effects (F-test against 0-FEM). All the 
test results are statistically significant, which supports the decision of using 1-way fixed 
effects models, for country. 
In general, the determinants present in the regression are relevant for the health of 
both men and women. However, we obtain different results by gender because throughout 
life the distribution and consequences of such determinants are different for each gender. 
Male/female differences in mortality and morbidity are essentially due to 
individuals’ different social roles, through marriage, parenthood, and employment; 
different lifestyle behaviors, such as cigarette smoking, and biological factors that also 
influence male/female mortality differences, particularly in infancy and prenatal life 
(Wingard, 1984). If we assume that individuals have different inter-temporal preferences, 
such differences may help to explain the variation in the consumption of cigarettes, alcohol, 
food and so on. 
According to Jourmand et al. (2008) and Afonso and St Aubyn (2006), GDP per 
capita is the most important determinant of health status. We expect a positive impact of 
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GDP per capita on a population’s health status because, higher income is related to higher 
quality of life. That is higher income may enable individuals to obtain better nutrition, 
housing, sanitation, public hygiene, schooling, etc., contributing in this way to reductions in 
premature mortality and improvements in life expectancy, both for men and women (Or, 
2001; Siddiqui and Mahmood, 1994; Wilkie and Young, 2009;). 
In this study, healthcare expenditure per capita is used as a proxy for the quantity of 
medical services provided to the population. According to Hadley (1982) this variable is 
preferable to the quantity of medical providers because variations in healthcare spending 
across countries better reflect the differences between the quantity and quality of medical 
services provided. Hence, we expect a positive relationship between healthcare spending 
per capita and our indicator. This is true for both genders in our study, which is consistent 
with the results obtained by Wolfe (1986); Crémieux et al. (1999); Hitiris and Posnett 
(1992); Jourmand et al. (2008). 
The effect of urbanization on the health status of populations can be ambiguous 
because it involves not only positive but also negative health related factors. On one hand 
people in cities have easier access to health care, education, food, and housing without 
bearing large transportation costs, on the other hand they are also subject to higher levels of 
pollution, congestion, road trauma and a higher burden of stress. People exposed to 
stressful lives have a higher risk of suffering from poor physical health, psychological 
distress, psychiatric disorders and substance abuse (Jemmot and Locke, 1984; Kessler et 
al., 1985; Turner and Lloyd, 1995). According to our results the negative urbanization 
effect dominates the positive effect for both genders when we consider the average life 
expectancy adjusted by perceived health status.  
Alcohol consumption is associated with an increased risk of liver cirrhosis, 
cardiovascular diseases and certain types of cancers. It is also linked to accidents and 
injuries, violence, problems at work, homicides and suicide (OECD, 2009). According to 
Substance Abuse and Mental Health Services Administration (SAMHSA) (2010) women 
drink less alcohol and have fewer alcohol-related problems than men. Such phenomenon 
can be attributed to biological and psychosocial factors such as genetic factors, alcohol 
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reactivity or sensitivity, social sanctions, gender roles, motives and expectancies, etc. 
(Blume, 1991; Gomberg, 1988; Nolen-Hoeksema, 2004). These factors can explain in part 
the different results obtained in men and women, as it is statistically significant for men but 
not for women (Ross and Bid, 1994). According to Or (2001) and McCartney et al. (2011), 
the impact of alcohol consumption on male premature mortality is slightly more 
pronounced than in women, accounting for 10-30 percent of the gender gap in European 
countries. 
McCartney et al. (2011) demonstrate that smoking accounts for 40-60 percent of the 
mortality difference by gender in European countries. In our study the variable smoking is 
not statistically significant, which is consistent with the work developed by Johansson and 
Sundquist (1999) and Miller and Frech (2000). This result may be due to the fact that there 
exists a time lag between smoking and the development of health problems (lung and other 
types of cancer, emphysema and other chronic lung diseases), which implies that the full 
long-run consequences of smoking at the aggregate level are probably not yet visible. 
The variable proportion of total healthcare expenditure financed by the government 
measures government intervention in the healthcare sector. The intervention of the 
government in the health sector can have either a beneficial or negative impact on the 
sector. By financing healthcare services, the government may enable individuals to access 
healthcare services, who otherwise would not have access to such services without the 
government intervention. However, the government intervention can be done at the cost of 
excessive regulation (setting maximum prices and defining wages, for example) which may 
affect the quantity and quality of the services provided in the health sector, affecting in this 
way the health status of the population (Santerre et al., 1991). According to Ahlbrandt 
(1973), Brennan and Buchanan (1980), and Stigler (1971) excessive government 
intervention in the healthcare sector has negative, rather than beneficial, consequences on 
the total performance of the healthcare sector. In the work developed by Or (2001), public 
intervention in the healthcare sector has a negative and significant coefficient for men, 
which means that this variable does not appear to have a significant role in explaining the 
reduction of premature mortality. 
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To capture the efficiency of home healthcare, we use as a proxy for education level 
the amount of public spending on education as percentage of GDP due to the unavailability 
of more direct measures of educational attainment. The different impact of education on 
both genders can be due to biological differences. Men and women may achieve similar 
educational outcomes, given the same inputs, but because of biological differences, the 
same healthcare inputs may result in very different health outcomes. 
Different authors have studied the effect of education on health over the years. 
Grossman (1972a, 1972b and 1976), Berger and Leigh (1989), and Leigh (1983) tested and 
validated the hypothesis that schooling increases the efficiency of household health 
production. This is possible because schooling improves the knowledge of the relationship 
between health behaviors and health outcomes, leading people to choose healthy behaviors 
and use healthcare resources more efficiently. People with a higher education level are less 
likely to smoke and drink and more likely to exercise. Education not only improves health 
directly (through more healthy lifestyles) but also indirectly through work and economic 
conditions (Ross and Wu, 1995). 
According to Ricci and Zachariadis (2008) when the average patient is more 
educated the probability of physicians adopting and implementing new treatments is higher 
since these individuals are more receptive to new medical knowledge. Generally education 
is directly linked with health literacy. “Health literacy implies the achievement of a level of 
knowledge, personal skills and confidence to take action to improve personal and 
community health by changing personal lifestyles and living conditions. Thus, health 
literacy means more than being able to read pamphlets and make appointments. By 
improving people’s access to health information, and their capacity to use it effectively, 
health literacy is critical to empowerment. Health literacy is itself dependent upon more 
general levels of literacy. Poor literacy can affect people’s health directly by limiting their 
personal, social and cultural development, as well as hindering the development of health 
literacy” WHO (1998). 
However, according to our results, education is not a statistically significant 
determinant of health status for women, but is for men. The positive impact of education on 
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health status of the population is shown in Siddiqui and Mahmood (1994). In turn, 
Crémieux et al. (1999) and Grubaugh and Santerre (1994) have found little empirical 
support for the relationship between education and health indicators. 
Other variables were tested such as sugar consumption (kilos per capita); the 
number of doctor visits per capita, the unemployment rate, the number of hospitalizations 
per million population, the number of professionally active physicians per million 
population, pharmaceutical sales per capita in US dollars, converted at economy-wide PPP, 
the proportion of long term care recipients in institutions (other than hospitals) and homes 
relative to the total population, among others. However, such variables were not 
statistically significant, which led to their exclusion from the analyses. 
An additional analysis was done to test for possible time breaks during the period in 
question. However, the results obtained did not suggest the existence of any time breaks. 
Such conclusions might be due to the fact that the variables in the regression already 
capture endogenously such an effect or because there are not any significant time breaks 
over the period analyzed. Moreover, we also considered the hypothesis of fixed effects on 
time that were refuted in the respective significance tests. 
 
4.6.1 Government intervention in the health sector 
The fact that governments provide public money to the healthcare sector does not 
imply that these funds are converted into effective services, due to possible inadequate 
institutional capacity and to inefficient and inequitable uses of resources. Furthermore, the 
net effect of public intervention in the healthcare sector depends on the severity of market 
failures. 
In this sense, public spending can encourage the private sector to move away from 
healthcare market as a result of an increase in public supply (public spending in the health 
sector may crowd out private spending in primary healthcare, reducing competiton in the 
healthcare market, which will decrease, according to Culyer et al. (1990), the potential 
gains in efficiency, quality, and consumer choice present in competitive markets): 
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“…extending publicly funded health care could merely crowd out the consumption of 
equally effective private services. Even if the government were to deliver health services 
effectively, the health impact would depend not on the total use of public services but rather 
on how public provision affected total use of all services” (Filmer et al, 2000, pp. 214). 
Despite public financing of healthcare expenditure providing wider access to 
healthcare, which may allow the improvement of health outcomes, there is also the 
possibility that the increase in public financing can lead to less efficient provision of 
healthcare services and worsen health outcomes (Berger and Messer, 2002). 
Generally, public spending in healthcare services can affect health status through 
four distinct mechanisms: the composition of public spending; the output of the public 
sector; the net impact of public sector supply on overall consumption; and the health 
production function (Filmer et al., 2000).  
According to some empirical studies about the impact of government intervention 
on infant mortality or child mortality, public expenditure on health as a share of GDP has 
no or a small impact on such indicators (Carrin and Politi, 1996; Demery and Walton, 
1998; Filmer and Pritchett, 1997; Musgrove, 1996; Santerre et al., 1991;). Bidani and 
Ravallion (1997) find a relatively small effect of public spending on aggregate health status 
(of the poor and non-poor taken together). Berger and Messer (2002) found a positive and 
significant association between the share of healthcare spending financed by the 
government and mortality. 
Although some people argue that there should be more public spending on primary 
healthcare, there exists little evidence on the beneficial impact of such spending on health 
indicators. As previously mentioned, some authors argue that this is because greater 
government intervention in the health sector may come at the cost of unnecessary 
regulation, being more likely to have an adverse impact rather than a beneficial impact on 
the performance of the healthcare sector (Ahlbrandt 1973; Brennan and Buchanan 1980; 
Stigler 1971). Many studies done in other areas of the economy (the transportation sector, 
education, postal system) show that governmental intervention and regulation can affect 
total output (quantity and quality) (Baumol, 1989). 
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4.6.2 Technological Composite Index 
 
“I am going to talk about a particular chapter in the 
history of disease, a chapter characterized by the surprising 
fact that the net effect of successful technical innovations 
used in disease control has been to raise the prevalence of 
certain diseases and disabilities by prolonging their average 
duration.” 
Gruenberg (1977, pp. 3) 
 
Technological progress in the healthcare sector makes it possible to avoid the death 
of some patients by curing certain previously fatal pathologies, increasing the survival rate 
and consequently the number of chronically ill people. In this way, some technological 
advances in healthcare did not arise to prevent or cure diseases, but to keep people alive, 
which is the case of organ transplantation, radiotherapy and chemotherapy (Kumar and 
Ozdamar, 2004). 
With the aim of evaluating the impact of technological innovation in life expectancy 
adjusted by perceived health status, we decided to construct a technological composite 
index able to reflect the technological level of the countries in the healthcare sector. 
 The indicators used in the construction of the composite index have been collected 
from the OECD database, according to available data. The methodology behind the 
construction of each variable was based on the work by Nardo et al. (2005), in which the 
weights of different indicators were computed using factor analysis. 
In Appendix B Table B.9, we list the indicators, which constitute the present index 
with their respective weights. This index has two main groups of variables: group one 
(MRI, MAM, RTE, LITH and MRIE) corresponds to healthcare machinery available in the 
country, while group two (END, FUKIDNEY, BONE, HEART, LIVER, LUNG and 
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KIDNEY) represents the most innovative medical procedures over the past few years. By 
incorporating these two groups we want to replicate, in the composite index, the treatment 
substitution effect and the treatment expansion effect presented by Cutler and McClellan 
(2001). 
From Table 4.7 we can see that technological innovation contributes negatively to 
life expectancy adjusted by the perceived health status. Initially we considered this result a 
little strange. However, after some additional research we came across what Gruenberg 
(1977) calls “the failure of success”. 
According to Gruenberg (1977, pp. 781) medical research instead of improving life 
and reducing diseases, “it produced tools which prolong diseases, diminished lives and so 
increase the proportion of people who have a disabling or chronic disease. That is a major 
but unintended effect of many technical improvements stemming from health research. 
These increasingly common chronic conditions represent the failures of success. Their 
growing prevalence and longer duration are a product of progress in health technology.” 
In this sense, our result confirms in part the following statement “…the techniques 
we have to improve life expectation perpetuate sick lives more than they do healthy lives...” 
(Gruenberg, 1977, pp. 794). To confirm completely the theory defended by Gruenberg 
(1977) we have to analyze the effect of our technological composite index on life 
expectancy. 
Using the same sample and the same explanatory variables used in the estimation of 
life expectancy adjusted by perceived health status, we estimated a new regression using 
this time life expectancy as a dependent variable, in order to ascertain the effect of 
technological innovation on life expectancy. In Table 4.7 we present the estimated 
coefficients for the composite technological index and for the composite technological 
index to the power of the square (the other estimated coefficients of the regression may be 
consulted in Annex B, Table B.10). 
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Table 4.7. Effect of technological composite index on life expectancy 
 INDEX INDEXSQ 
Men 1.44872
b
 -2.150789
a
  
Women 4.650939
a
  -5.882433
a
 
Note: According to this, the technological composite index (INDEX) has a positive effect on life 
expectancy, that is, an increase in INDEX will lead to an increase in life expectancy. a, b represent 1% 
and 5% levels of significance. 
 
As it is possible to see, technological innovation has a positive and significant effect 
on life expectancy in both genders, which together with the previous results supports the 
hypotheses developed by Gruenberg (1977). In order to analyze in more detail the two 
effects we decided to construct the graphs in Figure 4.7. 
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Figure 4.7. The effect of the technological composite index on LEAPHS and health expectancy 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Countries on the left side of 0.4 for health 
expectancy and LEAPHS: Chile; Israel; 
Hungary; Poland; Estonia; Slovakia; Ireland; 
Australia; UK and Slovenia. Countries between 
0.4 and 0.46: Luxembourg and Czech Republic. 
Countries on the right side of 0.46: Canada; New 
Zealand; Japan; Germany; Denmark; 
Netherland; France; Finland; Italy; Belgium; 
Norway; Austria; Iceland; Sweden; Portugal; 
Spain; Switzerland and USA. 
 
Men Women 
Note:.Countries on the left side of 0.34 for health 
expectancy and LEAPHS: Chile; Israel; Hungary 
and Poland.  
Countries between 0.34 and 0.47: Estonia; Slovakia; 
Ireland; Australia; UK; Slovenia; Czech Republic; 
Luxembourg and Canada.  
Countries on the right side of 0.47: New Zealand; 
Japan; Germany; Denmark; Netherland; France; 
Finland; Italy; Belgium; Norway; Austria; Iceland; 
Sweden; Portugal; Spain; Switzerland and USA. 
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Analyzing in more detail these graphs it is possible to conclude that: 
 For men (women), between the values 0 and 0.34 (0.4), more 
investment in health technologies will lead simultaneously to increases in life 
expectancy and decreases in LEAPHS. That is, increases in the technological level 
will only increase the number of years with disability – “extension of life…also…an 
extension of disease and disability” (Gruenberg, 1977, pp. 5). This conclusion is in 
accordance with the theory developed by Gruenberg (1977) due to the fact that the 
countries, which currently are located to the right side of 0.34 (0.4) for men 
(women), were in this interval in the 60’s and 70’s. 
 From 0.34 (0.4) additional technological investment will begin to 
cancel out the positive effects of past technological investments in health 
expectancy, reaching its limit for index values greater than 0.67 (0.8) for men 
(women). 
 Starting from 0.47 (0.46) there is a positive contribution of 
technological innovation in LEAPHS but negative in life expectancy for men 
(women). In this case, the new technologies help to increase LEAPHS, reducing the 
years of life with disability.  
 According to these figures and the increases seen in life expectancy 
over the last years, it is possible to conclude that, in the countries on the right hand 
side of 0.34 (0.4) there are other determinants that contribute positively to life 
expectancy, such as changes in lifestyles, diet, medical prevention, and economic 
growth. 
 In these graphs it is also possible to note that the UK seems to be 
relatively less technologically developed than other countries in the health sector. 
This result is consistent with Boyle (2011, pp. 185) “...the United Kingdom has had 
relatively few CT scanners and MRI units per head of population compared with 
other OECD countries”. 
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The differences between the two graphs are essentially due to health differences between 
genders. While men generally suffer from diseases that shorten life, the disease pattern in 
women leads to many women living in sickness or illness conditions (Altman and 
Bernstein, 2008), which leads to a greater demand for healthcare services by women. This 
happens essentially due to biological risks; risks acquired through social roles; lifestyle and 
illness behaviors (Case and Paxson, 2005; Waldron, 1985; Wingard, 1984). 
In addition, the graphs show that, initially the countries began to invest essentially 
in means of diagnosis, which has no impact on the quality of a patient’s life. In this phase, 
the diagnosis and treatment of diseases is more important than the treatment of the sick. 
This phase is characterized by increases in the number of Computed Tomography 
Scanners; Positron Emission Tomography scanners, Magnetic Resonance Imaging; Digital 
Subtraction Angiography and Life Support Machines. 
Additionally the nature of health problems has changed. Nowadays, chronic 
diseases are more frequent (for example: diabetes, obesity, and cholesterol) affecting not 
only the adult population but also children and the elderly.  
Over time, countries began to invest more in technologies and procedures that take 
into account not only treatment of diseased but also the prevention of diseases and the 
quality of patients’ lives. This became possible through the development of genetics, 
nanotechnology and robotics, which allowed the development of non-invasive and low 
invasive medical devices. Some of these developments have the potential to prolong and 
improve lives. Such technologies that have improved quality of life have included the 
pacemaker; insulin pen; human papilloma virus vaccine; natural orifice surgery; Ventricular 
Assist Device, human genome mapping, etc. 
The decline in the mortality rate over the years gives more importance to chronic 
diseases and their consequences (for example: the productivity reduction; prolonged 
disability; the need for care and finally death). In this way, some countries decided to 
develop integrated long-term care (convalescent care, recovery and reintegration of 
chronically ill patients and people in situations of dependency) with the aim of increasing 
the quality of life of patients with such diseases.  
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There is also a greater concern for investing in medical procedures and technologies 
focused essentially on improving a patient’s quality of life instead of investing in 
technologies directed to prolonging a patient’s life. Examples of this are cataract operations 
and prostheses. 
 
 
4.7 Conclusion 
 
The aims of this paper were to determine if the concern surrounding healthcare 
expenditure is legitimate by evaluating the return of such spending in quantitative (life 
expectancy) and qualitative (morbidity and disability) terms. 
Due to several problems inherent to the data - its specificity, its short time 
dimension, and the rare country coverage of some healthcare outcomes measures, we 
decided to construct a new health status indicator that combines mortality and morbidity, 
through the adjustment of life expectancy to the quality of years lived – LEAPHS. 
Using a panel data set of thirty OECD countries from 1980 to 2011, we estimated 
how various socio-economic, environment, lifestyle and technological factors affect this 
health status indicator. Through this analysis we found several interesting results. 
Almost all the variables considered were found to be significant and consistent with 
the existing literature despite the health outcome measure used being different. Among the 
significant variables were total healthcare expenditure per capita (Hitiris and Posnett, 
1992), GDP per capita; the proportion of the urban population; health expenditure financed 
by the government; and the technological composite index. 
The main conclusion that emerges from this study is that the concern around the 
amount of healthcare expenditure per capita should not be focused on the total expenditure 
per se, but instead directed to the amount financed by the government. 
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Other important conclusions are related to the technological composite index. 
According to our results, most health technologies used until now serve mainly to prolong 
sick lives instead of to ensure a healthy life: “…the techniques we have to improve life 
expectation perpetuate sick lives more than they do healthy lives...” (Gruenberg, 1977, pp. 
794). This conclusion may change through the discovery/development of new technologies, 
medical care services and medical techniques that offer better quality of life to patients, for 
example through integrated long term care, which may lead to a different configuration in 
the graphs presented in Figure 4.7. 
In addition to these conclusions, the results obtained also confirm that there is a 
significant potential for public health initiatives such as anti-drinking campaigns and 
compulsory education to improve health status. 
Despite its strengths there are some limitations to this study. For example it was not 
possible to obtain information about the degree of equity in health status across the 
population, something important in the definition of healthcare policies. Additionally, 
existing data about the amount of healthcare expenditure does not allow a detailed analysis 
of such expenditure, i.e., to know in which areas within the health sector money is being 
spent. The same concern applies to healthcare spending from the government – we cannot 
identify which areas within the sector receive financing. It is also important to know how 
resources are being allocated and not just how much money is being spent. 
Another limitation is the impossibility of using other health indicators, due to the 
lack of time series data and rare country coverage, to compare and validate the results that 
we obtained. 
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Annex B 
 
Table B.8. Descriptive statistics 
Variable Mean St. Deviation Min Max 
GDP per capita 10.10 0.41 9 11.34 
Healthcare expenditure per capita 7.61 0.54 6.16 8.99 
Urban population 4.33 0.14 3.91 4.58 
Alcohol consumption 2.26 0.32 0.69 2.88 
Tobacco consumption 2.75 0.19 2.09 3.22 
Hospital beds 1.7 0.43 0.83 2.75 
Health expenditure financed by 
Government 
4.28 0.18 3.66 4.56 
Health and social employment 3.75 0.45 2.48 4.76 
Public spending on education 1.68 0.2 1.11 2.17 
Fat intake 4.88 0.18 4.21 5.14 
INDEX 0.39 0.07 0.25 0.53 
LEAPHS Men 57.59 8.81 12.55 92.34 
LEAPHS Women 57.02 9.16 32.64 73.19 
Note: This table presents the descriptive statistics of the explanatory variables and of LEAPHS. 
 
 
Table B.9. Composition of the technological composite index 
Variables Description Weight 
MRI 
Magnetic Resonance Imaging units, total – Per million 
population. 
0.0938 
MAM Mammography, total – Per million population. 0.0983 
RTE Radiation therapy equipment, total – Per million population. 0.1202 
LITH Lithotripters, total – Per million population. 0.0483 
MRIE 
Magnetic Resonance Imaging exams, total – Per million 
population. 
0.1085 
END End-stage renal failure patients – Per 100.000 population. 0.0947 
FUKIDNEY Functioning kidney transplants – Per 100.000 population. 0.1103 
BONE Bone marrow transplants – Per 100.000 population. 0.0454 
HEART Heart transplants – Per 100.000 population. 0.0597 
LIVER Liver transplants – Per 100.000 population. 0.0602 
LUNG Lung transplants – Per 100.000 population. 0.0733 
KIDNEY Kidney transplants – Per 100.000 population. 0.0872 
Notes: This table displays the variable names, definitions and respective weights of the variables that 
constitute the technological composite index. 
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Table B.10. Estimated coefficients for health expectancy 
Variables Women Men 
GDP per capita 0.33 1.1
a
 
Healthcare expenditure per 
capita 
-0.43
c
 -0.46
c
 
Hospital beds 0.18 -0.06 
Public spending on education 0.22 0.39
a
 
Urban population -3.45
a
 -2.3
a
 
Health expenditure financed by 
General Government 
0.33 -0.23 
Alcohol consumption -0.65
a
 -0.96
a
 
Health and social employment -0.2 -0.89 
Tobacco consumption 0.3
a
 0.37
b
 
Fat intake -0.55
c
 -0.76
c
 
INDEX 4.65
a
 1.45
b
 
INDEXSQ -5.88
a
 -2.15
a
 
CONS 92.3
a
 80.98
a
 
Note: In this table we present the coefficients of the regression used to determine the impact of 
technological composite índex on health expectancy.  
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5.1 Conclusion 
 
 
Throughout the previous chapters we have discussed different topics related to the 
field of Health Economics, namely (i) the origin of the field and the works of its leading 
authors, (ii) the measurement of health care costs, and (iii) the impact of these increased 
costs on population health. Furthermore, our analysis concluded that several main factors 
over the last few decades have contributed to an increase in healthcare spending, focusing 
especially on the impact of technological innovation in the healthcare sector.  
In the final chapter we tried to assess if the present concern surrounding rampant 
healthcare expenditure growth is really legitimate, while also evaluating and measuring the 
return of such expenditures in quantitative (life expectancy) and qualitative (morbidity and 
disability) terms. To accomplish this, we constructed a new health status indicator able to 
consolidate mortality and morbidity into a single composite measure. The main conclusion 
that emerged is that the concern should not be focused on the total healthcare per capita 
expenditure per se, but rather instead directed to the amount financed by the government. 
Our results suggest that it is important for the countries analyzed in our sample to 
reconsider the proportion of their health care expenditures that are publicly financed. 
With respect to the determinants of healthcare expenditure, many of our conclusions 
reinforced findings that were also found in the previous literature, such as in papers by 
Barros (1998) and Okunade et al. (2004). Yet, several other results regarding the influence 
of technology were novel. In addition, we showed that technological innovation has a 
differential positive impact on costs depending on a country’s stage of development of 
technology, i.e. increases in the health expenditure per capita driven by technological 
innovation exhibited diminishing returns. 
Ultimately, these results allow us to conclude that ever-increasing investments into 
technological innovation can efficiently and effectively save resources. Despite the initial 
effort of required investment, additional investments are susceptible to being offset from 
efficiency gains through the use of technology. This fact may potentially lead to an increase 
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in global divergence or inequity between countries with respect to technological level in the 
healthcare sector. For example, countries with lower technological levels in healthcare 
(such as Mexico) do not benefit from the resource savings that countries with a higher 
technological level (such as the USA or Switzerland) benefit from. Thus, countries with 
higher technological levels will be open to investing in technological innovation, given the 
greater marginal benefit they receive. This fact may also be exacerbated by an inherent 
weak capacity of certain countries, particularly those with lower technological levels, to 
invest in more technologies due to the initial costs that it entails. 
Amongst our other notable results in the study, most health technologies used until 
now serve mainly to prolong life instead of to ensure a healthy life: “…the techniques we 
have to improve life expectation perpetuate sick lives more than they do healthy lives...” 
(Gruenberg, 1977, pp. 794). This conclusion may change with the discovery/development 
of new technologies, medical care services and medical techniques that offer better quality 
of life to the patients, for example through integrated long term care. 
However, it is important to point out that despite several strengths, there are some 
limitations to this study. For example it was not possible to obtain information about the 
degree of equity in health status across the population, something important in the 
definition of healthcare policies. Moreover, the existent data about the amount of healthcare 
expenditure does not allow a detailed analysis of such expenditure, i.e., an analysis of 
where within the health sector money is being spent. This same concern applies to 
healthcare spending from the Government – we cannot identify which areas within the 
sector receive financing. Presently, it is easier to understand how much money is being 
spent in the health industry as opposed to how the resources are being spent.  
The inability to consider ICTs in the technological composite index was another 
limitation of this study. This occurred due to the inexistence of certain variables that were 
able to reflect the use of the information and communication technologies in the healthcare 
sector. Also, the impossibility of using others health indicators, due to their lack of time 
series data and rare country coverage, made it difficult to compare and validate the results 
that we obtained. 
General Conclusion 
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Despite these and other limitations inherent in international comparisons, we cannot 
forget that, these kinds of limitations do not prevent individual governments from defining 
health policies or/and the amount of healthcare spending based largely on some healthcare 
outcomes measures such as infant mortality and life expectancy. 
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